

June 2022



**NCDR<sup>®</sup>**

---

NATIONAL CARDIOVASCULAR DATA REGISTRY

**Presented Abstracts Based on  
NCDR<sup>®</sup> Registries**



## PRESENTED ABSTRACTS

### Table of Contents

AFIB ABLATION REGISTRY™ .....	3
CATHPCI REGISTRY® .....	4
CARE REGISTRY® .....	15
CHEST PAIN - MI REGISTRY™ .....	16
DIABETES COLLABORATIVE REGISTRY® .....	21
EP DEVICE IMPLANT REGISTRY™ (FORMERLY ICD) .....	22
IMPACT REGISTRY® .....	27
LAAO REGISTRY™ .....	28
PINNACLE REGISTRY® .....	29
PVI REGISTRY™ .....	34
STS/ACC TVT REGISTRY™ .....	35

June 2022

## AFib Ablation Registry™

1. **1:** The American College of Cardiology's NCDR Afib Ablation Registry: A Summary of Initial Data Including Patient Characteristics, Procedural Characteristics, and Adverse Events. E. Secemsky. **AHA 2020. Poster Presentation.**

## CathPCI Registry®

1. **N/A:** Association of Health Insurance Status with Coronary Risk Factors, Coronary Artery Disease, Interventions and Outcomes in India: ACC-NCDR CathPCI Registry. **ACC 2022. Oral Presentation.**
2. **610:** Nationwide trends and outcomes of percutaneous coronary interventions following diagnostic angiography by invasive, non-interventional cardiologists versus solo-interventionalists: Insights from the CathPCI Registry. F. Lima. **ACC 2021. Oral Presentation.**
3. **672:** In-Hospital Mortality Risk Prediction for Percutaneous Coronary Interventions: An Updated Model from The NCDR CathPCI Registry. **ACC 2021. Poster Presentation.**
4. **611:** Utilization Rates and In-Hospital Outcomes Associated with Intravascular Imaging–Guided PCI in the USA: An Analysis of the NCDR CathPCI Registry. **TCT 2021. Poster Presentation.**
5. **405:** Stent selection among patients with chronic kidney disease: Results from the NCDR CathPCI Registry. **CCI 2020. Poster Presentation.**
6. **381:** The Incremental Cost of Acute Kidney Injury After Percutaneous Coronary Intervention: Implications for Practice in The United States. C. McNeely. **ACC 2019. Poster Presentation.**
7. **477:** Duration of Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulants in Clinical Practice. J. Tobolski. **ACC 2019. Poster Presentation.**
8. **571:** Linking the NCDR CathPCI Registry with Administrative Claims to Determine Attribution of Repeat Revascularization Following Index Drug-Eluting Stent Implantation. S. Dhruva. **ACC 2019. Poster Presentation.**
9. **391:** Use and Effectiveness of Manual Aspiration Thrombectomy during Percutaneous Coronary Intervention for the Treatment of ST-Elevation Myocardial Infarction in the US: An Analysis from the NCDR CathPCI Registry. E. Secemsky. **ACC 2018. Poster Presentation.**
10. **419:** Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. J. Rymer. **ACC 2018. Poster Presentation.**
11. **426:** Current Landscape of Hybrid Revascularizations: A Report from the National Cardiovascular Data Registry. A. Lowenstern. **ACC 2018. Moderated Poster Presentation.**
12. **440:** Ad Hoc Percutaneous Coronary Intervention in Patients with Stable Coronary Artery Disease: A Report from the National Cardiovascular Data Registry. K. Faridi. **ACC 2018. Poster Presentation.**
13. **523:** Uptake and Utilization of Drug-Eluting Bioresorbable Vascular Scaffolds: A CathPCI Registry Study. A. Kirtane. **ACC 2018. Poster Presentation.**
14. **120B:** Association Between Operator PCI Volume and Long-term Outcomes in Older Adults: A Report from The NCDR CathPCI Registry. **ACC 2017. Oral Presentation.**
15. **168B:** Utilization of Heart Teams in the United States: Results from the Translating Outstanding Performance in Percutaneous Coronary Intervention (TOP PCI) Study K. Mingos. **ACC 2017. Moderated Presentation.**
16. **305A:** Association Between Operator PCI Volume and Long-term Outcomes in Older Adults: A Report from The NCDR CathPCI Registry. A. Fanaroff. **AHA 2017. Poster Presentation.**
17. **357:** Appropriateness and Outcomes of Percutaneous Coronary Intervention at Top-Ranked and Non-Ranked Hospitals in the United States. Sukul. **AHA 2017. Poster Presentation.**
18. **156:** Costs Associated with Trans radial Primary PCI among Elderly Patients with STEMI in the Medicare Fee-For-Service Beneficiaries. A. Amin. **ACC 2016. Moderated Poster Presentation.**
19. **168C:** Associations of Hospital Strategies and 30-Day Risk-Standardized Mortality Rates in Percutaneous Coronary Intervention. J. Curtis. **ACC 2016. Oral Presentation. TOP PCI Mortality Abstract.**
20. **248A:** Effectiveness of Bivalirudin Versus Unfractionated Heparin During Percutaneous Coronary Intervention Among Patients with Acute Myocardial Infarction in the United States. E. Secemsky. **ACC 2016. Moderated Presentation.**

## June 2022

21. **248B:** Temporal Trends and Operator Variation in Anticoagulant Use During Percutaneous Coronary Intervention for Patients with Acute Myocardial Infarction in the United States. E. Secemsky. **ACC 2016. Moderated Presentation.**
22. **305B:** Temporal trends and regional patterns of operator percutaneous coronary intervention volume in the United States. A. Fanaroff. **ACC 2016. Poster Presentation.**
23. **102:** Differences in Hospital Risk-Standardized Mortality Rates for Acute Myocardial Infarction by Patient Age Group: Implications for Hospital Outcome Profiling. K. Dharmarajan. **AHA 2016. Poster Presentation.**
24. **276:** Prognosis of Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries as Compared with Obstructive Coronary Disease. R. Dreyer **AHA 2016. Moderated Poster Presentation.**
25. **292:** Trends, Predictors and Outcomes of Coronary Artery Perforation During Percutaneous Coronary Intervention: Insights from NCDR CathPCI Registry. R. Nairooz. **AHA 2016. Moderated Poster Presentation.**
26. **303:** Patterns of Use and Outcomes of Antithrombotic Therapy in End Stage Renal Disease Patients Undergoing PCI: Observations from NCDR. J. Washam. **AHA 2016. Moderated Poster Presentation.**
27. **353:** Differences in Hospital Risk-Standardized Mortality Rates for Percutaneous Coronary Intervention by Patient Age Group: Implications for Hospital Outcome Profiling. K. Dharmarajan. **AHA 2016. Moderated Poster Presentation.**
28. **230:** Clinical Characteristics and Outcomes in patients undergoing PCI to LIMA grafts: a study from the ACC NCDR CathPCI registry. K. Yeo. **TCT 2016. Poster Presentation.**
29. **193:** Temporal Trends in Care and Outcomes of Patients with Cardiogenic Shock Undergoing Percutaneous Coronary Intervention: A Report from the NCDR®. S. Wayangankar. **ACC 2015. Oral Presentation.**
30. **194:** Utilization of Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention in the Setting of Cardiogenic Shock. S. Negi. **ACC 2015. Poster Presentation.**
31. **212:** Temporal Trends in Admission Status and Predicted Mortality Among Patients Undergoing Non-Acute Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data Registry. A. Vora. **ACC 2015. Oral Presentation.**
32. **264:** Impact of Institutional Review of PCI Appropriateness on Quality of Care and Outcomes: An Analysis from the Top PCI Study and the NCDR-CathPCI Registry. N. Desai. **ACC 2015. Moderated Poster Presentation.**
33. **216:** Association of State Certificate of Need Regulations with the Appropriateness of PCI Procedures. P. Chui. **AHA 2015. Poster Presentation.**
34. **224:** Blood Transfusion and the Risk of Contrast-Induced Nephropathy Among Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention. **AHA 2015. Poster Presentation.**
35. **244:** Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention - Findings from the NCDR-CathPCI Registry. **AHA 2015. LBCT.02 Poster Presentation.**
36. **151:** Association of Interventional Cardiology board certification and in-hospital outcomes of patients undergoing percutaneous coronary interventions. P. Fiorilli. **ACC 2014. Oral Presentation.**
37. **172:** Length of Hospital Stay and Associated Clinical Outcomes in Elderly Patients Following Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: A Report from the National Cardiovascular Data Registry®. R. Swaminathan. **ACC 2014. Poster Presentation.**
38. **176:** Trends in Uptake and In-Hospital Outcomes with 2nd Generation Drug Eluting Stents Between Men and Women Undergoing PCI: Results from the CathPCI Registry. U. Baber. **ACC 2014. Poster Presentation.**
39. **174:** Outcomes and Predictors of  $\beta$ -blockers Prescriptions at Discharge in Patients with Stable Angina Without Prior History of Myocardial Infarction or Systolic Heart Failure Undergoing Elective PCI: Results from the NCDR Cath-PCI Registry V. Parikh. **AHA 2014. Oral Presentation.**
40. **180:** Clinical Characteristics and In-hospital Outcomes of Cardiac Transplant Recipients with Allograft Vasculopathy Undergoing Percutaneous Coronary Intervention: Insights from The National Cardiovascular Data Registry. S. Krim. **AHA 2014. Poster Presentation.**

## June 2022

41. **243:** Performance on Hospitals on PCI Process Measures and Correlation With 30-Day Readmissions. P. Chui. [AHA 2013. Oral Presentation.](#)
42. **173:** The Association Between Change in Hospital-Level Use of Transradial PCI and Periprocedural Outcomes: Insights from the NCDR®. S. Bradley. [QCOR 2014. Poster Presentation.](#)
43. **171:** Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: A Report from NCDR. E. Brilakis. [TCT 2014. Oral Presentation.](#)
44. **175:** Women in Interventional Cardiology: Update in PCI Practice Patterns and Outcomes from the National Cardiovascular Data Registry. [TCT 2014. Oral Presentation/Late Breaking Clinical Trial.](#)
45. **178:** Effectiveness of Arterial Closure Devices for Preventing Bleeding Complications After Transfemoral Percutaneous Coronary Intervention: A Controlled Instrumental Variable Analysis from The National Cardiovascular Data Registry. [TCT 2014. Oral Presentation/Late Breaking Clinical Trial.](#)
46. **147:** The Prevalence and Outcomes of Transradial PCI For STEMI: Analysis from The NCDR®. D. Baklanov. [ACC 2013. Oral Presentation.](#)
47. **156:** Costs Associated with Transradial Primary PCI Among Elderly Patients with STEMI In the Medicare Fee-For-Service Beneficiaries. A. Amin. [ACC 2013. Moderated Poster Presentation.](#)
48. **157:** Clinical Outcomes following Glycoprotein 2b/3a Inhibition in Percutaneous Coronary Intervention for Acute Coronary Syndrome – Insights from the NCDR®. D. Safley [ACC 2013. Moderated Poster Presentation.](#)
49. **158:** Predicting Target-Vessel Revascularization among Older Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stent Era. C. Hess. [ACC 2013. Poster Presentation.](#)
50. **159:** Gaps in referral to cardiac rehabilitation after percutaneous coronary intervention in the United States: insights from the National Cardiovascular Data Registry. K. Aragam. [ACC 2013. Poster Presentation.](#)
51. **167:** Trans radial PCI Is Associated with Lower Cost in Medicare Fee-for-Service Beneficiaries following Elective PCI. A. Amin. [ACC 2013. Oral Presentation.](#)
52. **168A:** Development and validation of a simple risk score to predict 30-day readmission for percutaneous coronary intervention. K. Minges. [ACC 2013. Poster Presentation.](#)
53. **170:** Comparison of Visual Estimation with Quantitative Coronary Angiography in Patients Undergoing Percutaneous Coronary Intervention in Real-World Practice Settings: A report from the CathPCI. B. Nallamothu. [ACC 2013. Poster Presentation.](#)
54. **N/A:** The Effect of Insurance Status on Time to Percutaneous Coronary Intervention for Patients with ST Elevation Myocardial Infarction: Findings from the CathPCI Registry. A. Herring. [ACC 2013. Poster Presentation.](#)
55. **101:** A qualitative study of the organizational strategies of high- and low-performing PCI hospitals: Insights from TOP PCI. J. Curtis. [AHA 2013. Oral Presentation.](#)
56. **103:** Evaluation of the safety and effectiveness of embolic protection devices in saphenous vein graft interventions in clinical practice: Insights from the Medicare-linked NCDR CathPCI Registry, 2005 - 2009. M. Brennan. [AHA 2013. Poster Presentation.](#)
57. **122:** Are “All-Comer” Clinical Trials Representative of Contemporary Clinical Practice: A Linked Analysis of the Dual Antiplatelet Therapy (DAPT) Study and the National Cardiovascular Data Registry®. R. Yeh. [AHA 2013. Poster Presentation.](#)
58. **165:** Geographic regions with low PCI utilization perform more appropriate Percutaneous Coronary Interventions. M. Thomas. [AHA 2013. Oral Presentation.](#)
59. **166:** A tale of two states: Comparison of PCI case mix in New York and Michigan. T. Boyden. [AHA 2013. Oral Presentation.](#)
60. **141:** A Registry Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention: The Study of Access Enhancement for PCI for Women (SAFE-PCI for Women) Trial. S. Rao. [TCT 2013. Late Breaking Clinical Trial Oral Presentation.](#)
61. **153:** The Association of Diagnostic Coronary Angiography in Asymptomatic Patients and PCI Appropriateness: Insights from the NCDR. S. Bradley. [QCOR 2013. Oral Presentation: Best of Scientific Sessions.](#)
62. **161:** Costs of Contrast Induced Acute Kidney Injury. A. Amin. [QCOR 2013. Poster Presentation.](#)

## June 2022

63. **53:** Hospital Characteristics Associated with Providing Optimal Medical Therapy for Percutaneous Coronary Intervention Patients: A Report from the NCDR®. W. Borden. **ACC 2012. Oral Presentation.**
64. **59:** Do Extreme Risk Cases Impact Hospitals' Risk-Adjusted PCI Mortality Ratings? Results From The NCDR®. **ACC 2012. Oral Presentation.**
65. **105:** A Validated Contemporary Risk Model of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights from the NCDR Cath-PCI Registry. **ACC 2012. Oral Presentation.**
66. **111:** Practice Comparisons Between Japan and the United States - Early Results with Japanese Percutaneous Coronary Intervention Registry and Its Direct Comparison with the Cath/PCI Registry®. S. Kohsaka. **ACC 2012. Poster Presentation.**
67. **119:** Impact of Reduced Door to Balloon Times on Mortality in Patients Undergoing Primary PCI in the United States. D. Menees. **ACC 2012. Poster Presentation.**
68. **123:** Non-System Reasons for Delay In Door-To-Balloon Time And In-Hospital Mortality: A Report From The National Cardiovascular Data Registry®. R. Swaminathan. **ACC 2012. Oral Presentation.**
69. **128:** Survival after PCI or CABG in Older Patients with Stable Multivessel Coronary Disease: Results from the ACCF-STS Database Collaboration on the Comparative Effectiveness of Revascularization Strategies (ASCERT). **ACC 2012. Poster Presentation.**
70. **148A:** Contemporary Incidence and Predictors of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights from the Cath-PCI Registry®. T. Tsai. **ACC 2012. Oral Presentation.**
71. **117:** Effectiveness of Bleeding Avoidance Strategies in Women and Men Following Percutaneous Coronary Interventions: Report from the NCDR®. L. Thompson. **AHA 2012. Oral Presentation.**
72. **121:** Clinical Symptoms and Angiographic Findings of Patients Undergoing Percutaneous Coronary Intervention without Prior Stress Testing: Insights from the NCDR. **AHA 2012. Poster Presentation.**
73. **126:** Hospital PCI Appropriateness and In-Hospital Procedural Outcomes: Insights from the NCDR®. S. Bradley. **AHA 2012. Poster Presentation.**
74. **135:** Patterns of red blood cell transfusion use in patients undergoing percutaneous coronary intervention in contemporary clinical practice: Insights from the NCDR® CathPCI Registry. M. Sherwood. **AHA 2012. Oral Presentation.**
75. **142:** Do Interventional Cardiology Training Programs Have Worse Outcomes Early in the Academic Year? An Assessment of the "July Effect" from the National Cardiovascular Database Registry. B. Hawkins. **AHA 2012. Oral Presentation.**
76. **148B:** A Validated Contemporary Risk Model of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights from the Cath-PCI Registry®. T. Tsai. **AHA 2012. Oral Presentation.**
77. **N/A:** A Hospital Outcome Prediction Model in Percutaneous Coronary Intervention: Volume-Specific Analysis Based on Adverse Ratios and Risk Adjusted Mortality. J. Wei. **AHA 2012. Poster Presentation.**
78. **114:** Standardized Risk Model for Predicting Long-Term Bleeding After Percutaneous Coronary Intervention. P. Sharma. **TCT 2012. Oral Presentation.**
79. **61:** Percutaneous Coronary Intervention in Native Arteries Vs. Bypass Grafts in Prior Coronary Bypass Grafting Patients: A Report from The CathPCI Registry®. E. Brilakis. **ACC 2011. Poster Presentation.**
80. **75:** Characteristics and Outcomes of Percutaneous Revascularization of Unprotected Left Main Coronary Artery Stenosis In The United States: Results From The National Cardiovascular Data Registry, 2004-2008. M. Brennan. **ACC 2011. Oral Presentation.**
81. **76:** Acute Long-Term Outcomes in Older Diabetic Patients Receiving a Coronary Stent. W. Hillegass. **ACC 2011. Poster Presentation.**
82. **99:** Appropriate Use of Percutaneous Coronary Intervention in the United States: Insights from the NCDR's Cath/PCI Registry. P. Chan. **ACC 2011. Oral Presentation.**

83. **100:** Left-Dominant Coronary Artery Circulation is Associated with Higher In-Hospital Mortality Among Patients Undergoing Percutaneous Coronary Intervention in Acute Coronary Syndrome: Data from the American College of Cardiology National Cardiovascular Data Registry for Catheterization Percutaneous Coronary Intervention. S. Parikh. **ACC 2011. Oral Presentation.**
84. **107:** Long-Term Mortality Associated with Multivessel Versus Culprit Vessel Only Percutaneous Coronary Intervention for Patients with Acute Myocardial Infarction: Insights from The National Cardiovascular CathPCI Data Registry. T. Wang. **ACC 2011. Oral Presentation.**
85. **97:** Clinical and Angiographic Characteristics of Patients Undergoing Percutaneous Coronary Intervention Following Sudden Cardiac Arrest: Insights From the NCDR®. N. Gupta. **AHA 2011. Poster Presentation.**
86. **110B:** Contemporary Predictors of Post-Procedural Bleeding Complications Among Patients Undergoing Percutaneous Coronary Intervention (PCI): Results from the National Cardiovascular Data Registry (NCDR). S. Rao. **AHA 2011. Oral Presentation.**
87. **110C:** Hospital Variation in Bleeding Complications Following Percutaneous Coronary Intervention (PCI): Results from the National Cardiovascular Data Registry (NCDR). E. Peterson. **AHA 2011. Oral Presentation.**
88. **127:** Bleeding and Vascular Complications at the Femoral Access Site Following Percutaneous Coronary Intervention (PCI). D. Tavris. **AHA 2011. Oral Presentation.**
89. **N/A:** Physician Annual Volume and Clinical Outcomes following Percutaneous Coronary Intervention (PCI). K. Minges. **AHA 2011. Poster Presentation.**
90. **8:** Clinical Strategies and Bleeding Outcomes in Elderly Patients Undergoing Primary PCI: Results from the NCDR CathPCI Registry. J. Dodson. **QCOR 2011. Poster Presentation.**
91. **110A:** Temporal Shifts in Antithrombotic Therapy Help Explain Reduction in Bleeding Complications Among Patients Undergoing Percutaneous Coronary Intervention: Results from A Report from the National Cardiovascular Data (NCDR) CathPCI Registry. S. Subherwal. **QCOR 2011. Oral Presentation.**
92. **N/A:** Contemporary Patterns of FFR and IVUS Use Among Patients Undergoing PCI in the United States: Insights from the NCDR®. P. Datillo. **TCT 2011. Poster Presentation.**
93. **60:** Frequency and Predictors of Drug-Eluting Stent Use in Saphenous Vein Bypass Graft Percutaneous Coronary Interventions: A Report from the American College of Cardiology - National Cardiovascular Data Registry. E. Brilakis. **ACC 2010. Poster Presentation.**
94. **68:** Learning Curve in the Use of StarClose Vascular Closure Device: An Analysis of the American College of Cardiology-National Cardiovascular Data Registry. F. Resnic. **ACC 2010. Poster Presentation.**
95. **72A:** ST Elevation Myocardial Infarction Due to Left Main Culprit Lesions: Percutaneous. G. Zoghbi. **ACC 2010. Oral Presentation.**
96. **72B:** Left Main Culprit Lesion Myocardial Infarction in Patients with Prior Coronary Bypass Grafting: Percutaneous Coronary Intervention Outcomes. W. Hillegass. **ACC 2010. Poster Presentation.**
97. **91A:** Comparative Effectiveness of Bleeding Avoidance Therapies in PCI Patients: Analysis From The National Cardiovascular Data Registry®. S. Marso. **ACC i2 2010. Poster Presentation.**
98. **91B:** PCI-Related Bleeding Risk by Access and Non-Access Site in the National Cardiovascular Data Registry. S. Marso. **ACC i2 2010. Poster Presentation.**
99. **91C:** Comparative Effectiveness of Radial Access and Bivalirudin on PCI-Related Bleeding Events: Analysis from the National Cardiovascular Data Registry. S. Marso. **ACC i2 2010. Poster Presentation.**
100. **95:** Trends and Predictors of Length of Stay after Primary Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data Registry. S. Rao, C.T. Chin. **ACC 2010. Poster Presentation.**
101. **N/A:** Development of Two Registry-Based Measures Suitable for Characterizing Hospital Performance On 30-Day All-Cause Mortality Rates Among Patients Undergoing Percutaneous Coronary Intervention. J. Curtis. **ACC 2010. Poster Presentation.**
102. **109:** Association Between Periprocedural Bleeding and Long-term Mortality after Percutaneous Coronary Intervention in the Elderly: A Report from the National Cardiovascular Data Registry (NCDR)®. S. Rao. **AHA 2010. Oral Presentation.**



## June 2022

103. **96:** Comparison of Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention for Previously Stented Versus De Novo Culprit Lesions: Insights from the National Cardiovascular Data Registry CathPCI Registry. Chee Tang Chin. [AHA 2010. Oral Presentation.](#)
104. **67:** Temporal Trends in the Use of Thrombectomy During Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction in the United States. A. Michaels. [TCT 2010. Poster Presentation.](#)
105. **98:** Left Circumflex Occlusion in Myocardial Infarction: A Review of the Catheterization and Percutaneous Coronary Intervention Registry (CathPCI Registry®). K. Stribling. [TCT 2010. Poster Presentation.](#)
106. **53:** Patterns and Intensity of Medical Therapy in Patients Undergoing Percutaneous Coronary Intervention. W. Borden. [QCOR 2010. Poster Presentation.](#)
107. **104:** Impact of Predicted Bleeding Risk on the Cost-Effectiveness of Direct Thrombin Inhibition vs. Heparin Monotherapy for Patients Undergoing PCI. A. Amin. [QCOR 2010. Oral Presentation: Young Investigator Award.](#)
108. **29:** Organization and logistics in facilities that perform percutaneous coronary intervention without cardiac surgery backup on-site. M. Kutcher. [Academy Health 2009. Poster Presentation.](#)
109. **41:** A Clinical Risk Prediction Tool for Post-PCI Bleeding from the National Cardiovascular Data Registry. J. Lindsey. [ACC i2 2009. Poster Presentation.](#)
110. **N/A:** Annual case volume is not a strong predictor of bleeding complications after percutaneous coronary intervention: A report from the National Cardiovascular Data Registry. S. Rao. [ACC 2009. Poster Presentation.](#)
111. **N/A:** Comparison of Angiographic Findings and Door to Balloon Times at Hospitals that Do and Do Not Allow ED Cath Lab Activation: Insights from the NCDR CathPCI Registry and the D2B Alliance. R.C. Regan. [ACC i2 2009. Oral Contribution.](#)
112. **66:** In-hospital Outcomes following No-Reflow Phenomenon after Percutaneous Coronary Intervention in Acute Coronary Syndromes. A. Aggarwal. [AHA 2009. Oral Presentation.](#)
113. **N/A:** Long term outcomes of drug eluting vs bare metal stents in off-label lesions. M. Patel. [AHA 2009. Poster Presentation.](#)
114. **90A:** Contemporary Risk of In-Hospital Events in Dialysis Patients Undergoing Percutaneous Coronary Interventions: Insights From the ACC-NCDR Cath-PCI Registry. T. Tsai. [AHA 2009. Poster Presentation.](#)
115. **90B:** Renally Cleared Anti-Thrombotic Agents Among Dialysis Patients Receiving Percutaneous Coronary Interventions: Insights From the ACC-NCDR Cath-PCI Registry. T. Tsai. [AHA 2009. Oral Presentation: Finalist for Young Investigator Award \[YIA\].](#)
116. **92:** Variation in the rate of 'normal' elective diagnostic catheterization. A potential Quality Metric? P. Douglas. [AHA 2009. Oral Presentation.](#)
117. **15:** Changing Guidelines May Affect Assessments of Quality of Care for Patients Undergoing PCI. G. Lin. [ACC 2008.](#)
118. **27A:** Non-infarct Artery Intervention During Primary PCI for ST-segment elevation myocardial infarction May Be a Reasonable Strategy in Selected Hemodynamically Stable Patients: Results from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). M. Cavender. [ACC 2008.](#)
119. **27B:** Prevalence and In-hospital Outcomes of Multi-vessel PCI during Primary PCI for ST-segment elevation myocardial infarction: Results from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). M. Cavender. [ACC 2008.](#)
120. **47:** Clinical Characteristics and in Hospital Outcomes of Patients Undergoing Rescue Percutaneous Coronary Intervention Compared to Primary Percutaneous Intervention. S. Burjonrappa. [ACC 2008.](#)
121. **52:** Effect of Age on Outcome of Percutaneous Coronary Interventions: National Cardiovascular Database Registry Experience. M. Singh. [ACC 2008.](#)
122. **59:** Contemporary Predictors of Procedural Mortality Among Patients undergoing Percutaneous Coronary Intervention (PCI): Results from the ACC-NCDR. E. Peterson. [ACC 2008.](#)
123. **1:** Association of Primary Percutaneous Coronary Intervention Door-to-Balloon Time and Mortality in Patients Hospitalized with ST-Elevation Myocardial Infarction. S. Rathore. [AHA 2008.](#)

124. **5:** Interaction of Age and Glomerular Filtration Rare to Predict In-Hospital Mortality Following Percutaneous Coronary Intervention for Acute Myocardial Infarction. F. Cardarelli. [AHA 2008](#).
125. **48:** Incidence and Predictors of Stroke Associated with Percutaneous Coronary Intervention. A. Aggarwal. [AHA 2008](#).
126. **55:** Impact of long-term safety data and FDA warnings on drug-eluting stent use in clinical practice: A report from the National Cardiovascular Data Registry. R. J. Krone. [AHA 2008](#).
127. **56:** Clinical Significance of Post-Procedural Thrombolysis in Myocardial Infarction Flow in Patients with Cardiogenic Shock Undergoing Primary Percutaneous Coronary Intervention. R. H. Mehta. [AHA 2008](#).
128. **58:** Do Hospitals that Improve “Walk In” Door-to-Balloon Times for Primary Percutaneous Coronary Intervention Also Improve “Transfer In” Door-to-Balloon Times? T. Wang. [AHA 2008](#).
129. **71:** Patients without obstructive coronary artery disease and stress test results: An analysis from the National Cardiovascular Data Registry. M. Patel. [AHA 2008](#).
130. **28:** Utilization of Distal Embolic Protection in Saphenous Vein Graft Interventions (An Analysis of 19,546 Patients in the American College of Cardiology–National Cardiovascular Data Registry). K. Sameer. [ACC 2007](#).
131. **39:** Intermediate Volume Operators Attempt Percutaneous Coronary Intervention of Chronic Total Occlusions More Frequently Than Low- or High-Volume Operators: An Analysis from the American College of Cardiology-National Cardiovascular Data Registry Database of 45,826 CTO Patients. J. Grantham. [ACC 2007](#).
132. **51:** Comparison of Hospital Door-to-Balloon Times Reported by CMS and ACC-NCDR: Apples and Oranges? B. Nallamothu. [ACC 2007](#).
133. **N/A:** The Radial Approach to Percutaneous Coronary Intervention Is Associated with a Lower Risk for Complications Regardless of Radial Procedure Volume: A Report from the American College of Cardiology-National Cardiovascular Data Registry. S. Rao. [ACC 2007](#).
134. **25:** Challenges of Using Peri-Procedural Myocardial Infarction as a Quality Measure Among Patients Undergoing Percutaneous Coronary Intervention. T. Wang. [AHA 2007](#).
135. **39:** Current Practice Patterns in Percutaneous Treatment of Total Chronic Occlusions and the Association of Operator Volume with Treatment. J. A. Grantham. [AHA 2007](#).
136. **40:** The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National Cardiovascular Data Registry. A. Frutkin. [AHA 2007](#).
137. **41A:** Use of Arteriotomy Closure Devices and the Risk of Vascular Complications: An Analysis of 227,879 Patients in the ACC-NCDR. S. Mehta. [AHA 2007](#).
138. **41B:** Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Predictive Model From 302,152 Patients in the ACC-NCDR. S. Mehta. [AHA 2007](#).
139. **42:** Are we meeting the goals? Gender Analysis of Evidence Based Medical Therapies among patients presenting with an Acute Coronary Syndrome (ACS) who undergo Post-Percutaneous Coronary Intervention (PCI): Results from the ACC-NCDR Cath/PCI Registry. N. Akhter. [AHA 2007](#).
140. **44:** Anatomic Distribution of Culprit Lesions in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. T. Wang. [AHA 2007](#).
141. **45:** Validation of Mayo Clinic Risk Adjustment Model for In-Hospital Mortality following Percutaneous Coronary Interventions using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). M. Singh. [AHA 2007](#).
142. **46:** Characteristics and Outcomes of Patients Taking Warfarin Prior to Percutaneous Coronary Intervention. A. Aggarwal. [AHA 2007](#).
143. **57A:** Young Women Undergoing Elective PCI Procedures Have Higher Complications Rates Than Similarly Aged Men: Results from the ACC-NCDR Registry. J. Lichtman. [AHA 2007](#).
144. **57B:** Conventional Risk Factors Are Highest for Minority Women Presenting with Myocardial Infarction: Results from the ACC-NDCR Registry. J. Lichtman. [AHA 2007](#).

145. **N/A:** Absence of Flow-Limiting Coronary Artery Disease Among Patients Undergoing Emergent Cardiac Catheterization for ST Segment Elevation Myocardial Infarction in the National Cardiovascular Data Registry CathPCI Registry: Implications for Primary Angioplasty Programs. K. Ho. [AHA 2007](#).
146. **47:** Incidence and Predictors of Bleeding Among Patients Undergoing Rescue Percutaneous Coronary Intervention after Failed Fibrinolysis for ST-Elevation Myocardial Infarction. S. Burjonrappa. [TCT 2007](#).
147. **N/A:** Relationship Between Hospital PCI Volume and In-Hospital Major Adverse Clinical Events: The ACC-NCDR Results. L. W. Klein. [ACC 2006](#).
148. **N/A:** In-Hospital Outcomes in Patients with ACS Treated with Sirolimus and Paclitaxel Drug-Eluting Stents: Experience from the ACC-NCDR Database. E. Veledar. [ACC 2006](#).
149. **N/A:** A New Score Assessing Programmatic PCI Case Risk: The ACC-NCDR Complexity Score. L. W. Klein. [ACC 2006](#).
150. **2:** Time-to-Reperfusion in Patients Undergoing Inter-Hospital Transfer for Primary Percutaneous Intervention in the United States: Results from the National Cardiovascular Data Registry. B. K. Nallamothu. [AHA 2006](#).
151. **4:** Risk-Adjusted Mortality Analysis of Percutaneous Coronary Interventions by American College of Cardiology/American Heart Association Guidelines Recommendations. H. V. Anderson. [AHA 2006](#).
152. **6:** Effect of Insurance Status on Use of Drug-Eluting Stents versus Bare Metal Stents in Patients Undergoing Elective Percutaneous Coronary Intervention. R. Vicuna. [AHA 2006](#).
153. **22:** Lower Procedural Success and Higher Complications in Octogenarians with STEMI Referred for Emergency Cardiac Catheterization: Results from the American College of Cardiology—National Cardiovascular Data Registry. J. P. Curtis. [AHA 2006](#).
154. **N/A:** PCI in Asymptomatic Outpatients Undergoing Cardiac Catheterization: Results from the American College of Cardiology—National Cardiovascular Data Registry. J. P. Curtis. [AHA 2006](#).
155. **N/A:** Post-Procedural Outcomes in Hispanics, Asians, American Indians, and Caucasians Following Percutaneous Coronary Intervention. A. D. Patel. [AHA 2006](#).
156. **N/A:** Race and Gender Differences in Post-Procedural Outcomes Following Percutaneous Coronary Intervention in African Americans and Caucasians. A. D. Patel. [AHA 2006](#).
157. **N/A:** Contemporary Analysis of the Association between Hospital Volume and In-Hospital Death in Patients Undergoing Percutaneous Coronary Intervention: Results from the National Cardiovascular Data Registry. B. K. Nallamothu. [AHA 2006](#).
158. **N/A:** Renal Failure, In-Hospital Mortality and Unplanned Coronary Artery Bypass Grafting Among 85 Years and Older Percutaneous Coronary Intervention Patients with Non-ST Elevation and ST Elevation Myocardial Infarction: Experience from the American College of Cardiology—National Cardiovascular Data Registry. E. Veledar. [American Society of Nephrology 2006](#).
159. **11B:** Demographic Variations in Percutaneous and Surgical Revascularization of Unprotected Left Main Coronary Artery Stenosis: A Report from the American College of Cardiology—National Cardiovascular Data Registry. H. W. Huang. [CRT 2006](#).
160. **N/A:** Patterns of Clopidogrel Use in Patients Undergoing Staged Percutaneous Coronary Intervention: A Report from the American College of Cardiology—National Cardiovascular Data Registry. A. J. Baumgarten. [CRT 2006](#).
161. **N/A:** Peri-Procedural Complications of Sirolimus-Eluting and Paclitaxel-Eluting Stent Use in Patients Undergoing Intervention in Diseased Saphenous Vein Grafts. S. Chaparro. [CRT 2006](#).
162. **N/A:** Comparison of In-Hospital Outcomes in Diabetics and Non-Diabetics Using the Paclitaxel and Sirolimus Drug-Eluting Stents: Results from the ACC-NCDR. E. Veledar. [CV Quality Forum 2006](#).
163. **11A:** Trends in Percutaneous versus Surgical Revascularization of Unprotected Left Main Coronary Artery Disease in the Drug-Eluting Stent Era: A Report from the American College of Cardiology – National Cardiovascular Data Registry (ACC-NCDR). H. Huang. [AHA 2005](#).

164. **10:** Significantly Increasing Trend in Coronary Angioplasty Without Onsite Surgical Backup: A Report from the American College of Cardiology – National Cardiovascular Data Registry. S.K. Dey. [AHA 2005](#).
165. **14:** Culprit or Multi-vessel PCI in patients with ACS? Why not finish the job? S. Brener. [AHA 2005](#).
166. **23:** Comparison of in-hospital mortality for PCI patients receiving DES comparing Sirolimus vs Paclitaxel with or without acute myocardial infarction (AMI); the American College of Cardiology National Cardiovascular Data Registry (ACC/NCDR) experience. W. Weintraub. [AHA 2005](#).
167. **N/A:** Is the Obesity Paradox for Real? The Effect of Body Mass Index on Mortality Following Percutaneous Coronary Intervention for Those Presenting with an ST Elevation Myocardial Infarction. J. Tremmel. [AHA 2005](#).
168. **N/A:** On-site surgical backup as a predictor of mortality among PCI patients with STEMI, NSTEMI, or no AMI. J. K. Foster. [AHA 2005](#).
169. **N/A:** Relationship between Hospital Coronary Angioplasty Volume and In-hospital Mortality: Results from The American College of Cardiology - National Cardiovascular Data Registry. Z. Zhang. [AHA 2005](#).
170. **N/A:** Outcome of Patients 85 and Older Undergoing PCI for Chronic CAD, Non-ST elevation and ST elevation MI: Experience from the American College of Cardiology National Cardiovascular Data Registry. E. Veledar. [AHA 2005](#).
171. **N/A:** Safety and Efficacy of Three Strategies of Multi-Vessel Percutaneous Coronary Intervention: Same Session versus Multi-Session versus Multi-Hospitalization. J. C. Blankenship. [AHA 2005](#).
172. **N/A:** External validation of models of in-hospital mortality for acute myocardial infarction patients with and without ST-segment elevation following percutaneous coronary intervention. P. Kolm. [AHA 2005](#).
173. **N/A:** Severity of Coronary Disease in End-Stage Renal Disease Patients: Angiography Results from the American College of Cardiology - National Cardiovascular Data Registry. C. Jurkovitz. [American Society of Nephrology 2005](#).
174. **N/A:** Coronary disease risk profile of racial groups undergoing percutaneous coronary intervention - results from the American College of Cardiology - National Cardiovascular Data Registry. A.D. Patel. [Society for Cardiovascular Angiography and Interventions 2005](#).
175. **N/A:** Post-procedural outcomes of racial groups undergoing percutaneous coronary intervention - results from the American College of Cardiology - National Cardiovascular Data Registry. A. D. Patel. [Society for Cardiovascular Angiography and Interventions 2005](#).
176. **N/A:** Racial outcomes of lesion characteristics and coronary stent use on lesion success - observations from the American College of Cardiology - National Cardiovascular Data Registry. A.D. Patel. [Society for Cardiovascular Angiography and Interventions 2005](#).
177. **N/A:** Nationwide Use of Intracoronary Brachytherapy Since the Introduction of Drug Eluting Stents. R. Sangha. [Transcatheter Cardiovascular Therapeutics 2005](#).
178. **N/A:** The Influence of Body Mass Index on Mortality Following Percutaneous Coronary Intervention in Those Presenting with Unstable Angina or non-ST Elevation Myocardial Infarction: Is There an Obesity Paradox? J. Tremmel. [Transcatheter Cardiovascular Therapeutics 2005](#).
179. **N/A:** Risk adjusted modeling of in hospital mortality for insulin-dependent PCI patients receiving drug eluting stents; Experience from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). E. Veledar. [Transcatheter Cardiovascular Therapeutics 2005](#).
180. **N/A:** Assessment of the feasibility, safety, and success of trans radial access for percutaneous coronary intervention: A Report from the ACC-NCDR. A. Ahmed. [ACC 2004](#).
181. **N/A:** The risk of immediate percutaneous coronary intervention after thrombolytic therapy: A report from the ACC-NCDR. H. S. Naik. [ACC 2004](#).
182. **N/A:** Beneficial Effects of combined thrombolytic therapy and percutaneous coronary angioplasty in transfer patients with ST segment elevation myocardial infarction: A report from the ACC-NCDR. D. P. O'Neill. [ACC 2004](#).

183. **N/A:** Does the Use of Embolic Protection Devices Improve Clinical Outcomes in Saphenous Vein Graft Percutaneous Coronary Intervention? A Report from the American College of Cardiology—National Cardiovascular Data Registry. L. W. Klein. [AHA 2004](#).
184. **N/A:** Impact of Ethnicity and Gender Differences on the Prevalence of Angiographic Coronary Artery Disease in the ACC-NCDR. L. J. Shaw. [AHA 2004](#).
185. **N/A:** Patterns and outcomes of drug-eluting coronary stent use in clinical practice. S. V. Rao. [AHA 2004](#).
186. **N/A:** On- versus Off-Label Use of Drug-Eluting Coronary Stents in Clinical Practice: Report from the ACC-NCDR. S. V. Rao. [AHA 2004](#).
187. **N/A:** Predicting In-Hospital Mortality for Acute Myocardial Infarction Patients with and Without ST-Segment Elevation Following Percutaneous Coronary Intervention. P. Kolm. [Biometric Society Eastern North American Region 2004](#).
188. **N/A:** Bleeding Complications in Women Undergoing Glycoprotein IIb/IIIa Receptor Inhibition in Elective Percutaneous Coronary Intervention: A Report from the American College of Cardiology—National Cardiovascular Data Registry. H. S. Naik. [CV Quality Forum 2004](#).
189. **N/A:** Have recommendations for cholesterol-lowering therapy been effectively implemented in patients presenting for percutaneous coronary intervention with prior revascularization? A report from the ACC-NCDR. M. Levy. [TCT 2004](#).
190. **N/A:** Effect of Gender According to Age on In-Hospital Mortality in Patients with Acute Myocardial Infarction in the ACC-NCDR. S. C. Beinart. [ACC 2003](#).
191. **N/A:** Predictors of In-Hospital Outcomes of Percutaneous Coronary Intervention in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (UA/NSTEMI): A Report from the National Cardiovascular Data Registry. L. W. Klein. [TCT 2003](#).
192. **N/A:** The Expected Rate of Normal Coronary Arteriograms in the Cardiac Laboratory. B. D. McCallister. [ACC 2002](#).
193. **N/A:** Mortality After Emergent PCI in Cardiogenic Shock Secondary to Acute Myocardial Infarction and Usefulness of a Mortality Prediction Model. L. W. Klein. [ACC 2002](#).
194. **N/A:** Emergency CABG after Failed PCI in Contemporary Practice: A Report from the ACC-NCDR. M. A. Kutcher. [ACC 2002](#).
195. **N/A:** Gender Differences in Frequencies of Significant and Severe Coronary Disease in the ACC-NCDR. L. J. Shaw. [ACC 2002](#).
196. **N/A:** Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in Severe Coronary Artery Disease—Does Contemporary Practice Reflect Existing American College of Cardiology American Heart Association Guidelines? R. Gibbons. [AHA 2002](#).
197. **N/A:** Effect of Hospital Volume on PCI Outcomes in the ACC-NCDR. S. C. Beinart. [AHA 2002](#).
198. **N/A:** Relationship of Coronary Stenting and Glycoprotein IIb/IIIa Inhibitors to PCI Outcomes in Insulin-Dependent Diabetics: A Report from the American College of Cardiology—National Cardiovascular Data Registry. L. W. Klein. [AHA 2002](#).
199. **N/A:** Predictors of Outcome of Primary PCI in ST Elevation Myocardial Infarction in 6,521 Consecutive Cases During 2001: A Report from the American College of Cardiology—National Cardiovascular Data Registry. L. W. Klein. [AHA 2002](#).
200. **N/A:** Intervention in Saphenous Vein Grafts: A Predictive Model of Mortality Based on Clinical Presentation of 5,899 Consecutive Cases in the ACC-NCDR. L. W. Klein. [AHA 2002](#).
201. **N/A:** ACC-NCDR: A National Quality Measurement Program for Cardiac Catheterization Laboratories. R. G. Brindis. [CV Quality Forum 2002](#).
202. **N/A:** Relationship of Coronary Stenting and Glycoprotein IIb/IIIa Inhibitors to PCI Outcomes in Insulin-Dependent Diabetics: A Report from the American College of Cardiology—National Cardiovascular Data Registry. R. G. Brindis. [CV Quality Forum 2002](#).
203. **N/A:** Effect of Hospital Volume on PCI Outcomes in the ACC-NCDR. S. C. Beinart. [CV Quality Forum 2002](#).

## June 2022

204. **N/A:** Hospital Variability in Diagnostic Catheterization: Insights from the ACC-NCDR. M. Radford. [CV Quality Forum 2002](#).
205. **N/A:** The Influence of Diabetes on the In-Hospital Outcome of PCI in the ACC-NCDR. L. W. Klein. [ACC 2001](#).
206. **N/A:** Are Women at Increased Risk of Death after PCI? Results from the ACC-NCDR Database. H. V. Anderson. [ACC 2001](#).
207. **N/A:** Outcomes of PCI in Octogenarian Patients Who Present with Acute MI. L. W. Klein. [AHA 2001](#).
208. **N/A:** Clinical Risk Score to Predict the Likelihood of LM or 3-Vessel CAD for Patients in the ACC-NCDR. R. Gibbons. [AHA 2001](#).
209. **N/A:** How can the lesion classification system help predict PCI success and failure/complications? R. J. Krone. [AHA 2001](#).
210. **N/A:** Which is more important in measuring a PCI patient's risk of adverse outcomes, clinical state or lesion classification? R. J. Krone. [AHA 2001](#).
211. **N/A:** Quality Improvement Begins with Quality Data: An Automated Program for Insuring Data Completeness for the ACC-NCDR. R. E. Shaw. [Maryland Informatics 2001](#).
212. **N/A:** NO - Quality is More Important than Quantity. H. V. Anderson. [TCT 2001](#).
213. **N/A:** Variations in Risk-Adjusted Mortality with PCI: The ACC-NCDR. C. R. McKay. [AHA 2000](#).
214. **N/A:** Indications for Coronary Interventions by ACC Criteria: The ACC-NCDR. H. V. Anderson. [AHA 2000](#).
215. **N/A:** The Influence of Age on the In-Hospital Outcome of PCI: Results from the ACC-NCDR. H. V. Anderson. [AHA 2000](#).
216. **N/A:** Development of an Initial Model for Risk Adjustment of mortality Following Coronary Intervention: Results from the ACC-NCDR. R. E. Shaw. [AHA 2000](#).
217. **N/A:** Complications of Percutaneous Coronary Interventions: Preliminary Results from the ACC-NCDR. H. V. Anderson. [CV Quality Forum 2000](#).
218. **N/A:** An Automated Program for Insuring Data Quality for the ACC-NCDR. R. E. Shaw. [CV Quality Forum 2000](#).
219. **N/A:** Quest for an Evidence-Based Minimum Cardiac Cath Lab Dataset: Version 2.0. H. V. Anderson. [CV Quality Forum 2000](#).

June 2022

## CARE Registry®

1. **16:** Proximal versus Distal Embolic Protection for Carotid Artery Stenting. J. Giri. [ACC 2014. Oral Presentation.](#)
2. **5A:** Carotid Artery Stenting and Carotid Endarterectomy are Comparable Among Medicare Beneficiaries Treated in Routine Clinical Practice. J. Jalbert. [AHA 2014. Poster Presentation.](#)
3. **5B:** Potential Heterogeneity in the Effectiveness of Carotid Artery Stenting vs. Carotid Endarterectomy Among Subgroups of Medicare Beneficiaries in Routine Clinical Practice. J. Jalbert. [AHA 2014. Poster Presentation.](#)
4. **52:** Racial and Ethnic Variation in Utilization and Outcomes in Carotid Artery Revascularization: Analysis from the NCDR®. F. Lafit. [TCT 2013. Poster Presentation.](#)
5. **44:** Hospital Variation in Carotid Artery Stenting Outcomes- An NCDR Analysis. B. Hawkins. [QCOR 2013. Poster Presentation.](#)
6. **15A:** Carotid Artery Stenting (CAS) in the Elderly Population: Procedural Outcomes Stratified by Age. N. Ruggiero. [ACC 2012. Poster Presentation.](#)
7. **24:** Hemorrhagic and Ischemic Outcomes following Bivalirudin vs. Unfractionated Heparin during Carotid Artery Stenting: Analysis from the NCDR®. S. Wyangankar. [ACC 2012. Poster Presentation.](#)
8. **25A:** Unprotected Carotid Artery Stenting in Modern Practice: Insights from the NCDR®. J. Giri. [ACC 2012. Poster Presentation.](#)
9. **25B:** Comparative Effectiveness of Commonly Used Devices for Carotid Stenting. J. Giri. [ACC 2012. Poster Presentation.](#)
10. **15B:** Outcomes of CEA in the elderly in the CARE registry. K. Rajamani. [ISC 2012. Oral Presentation.](#)
11. **32:** Predicting In-Hospital Cardiovascular Events Following Carotid Artery Stenting: The Development of a Risk Model Using the NCDR-CARE Registry®. B. Hawkins. [SCAI 2012. Poster Presentation.](#)
12. **20:** Impact of timing of carotid artery stenting on outcomes in the symptomatic population. N. Ruggiero. [ACC 2011. Poster Presentation.](#)
13. **22:** Impact of contralateral carotid occlusion on clinical outcomes in patients undergoing carotid artery stenting (CAS) in the CARE registry. N. Mercado. [ACC 2011. Oral Presentation.](#)
14. **19:** Outcomes of Endovascular Treatment for Carotid Artery Restenosis following prior carotid artery stenting or endarterectomy. B. Hynes. [AHA 2011. Poster Presentation: Best Poster of Session.](#)
15. **9:** Influence of participation in clinical trials on outcomes after carotid artery stenting – results from the Carotid Artery Revascularization and Endarterectomy (CARE) Registry. R. Yeh. [ACC 2010. Poster Presentation.](#)
16. **11A:** Carotid revascularization immediately prior to urgent cardiac surgery: Practice patterns associated with the choice of carotid artery stenting (CAS) or endarterectomy (CEA) from the NCDR-CARE registry. C. Don. [ACC 2010. Poster Presentation.](#)
17. **11B:** Carotid revascularization immediately prior to urgent cardiac surgery: Clinical outcomes associated with the choice of carotid artery stenting (CAS) or endarterectomy (CEA) from the NCDR-CARE registry. C. Don. [ACC 2010. Poster Presentation.](#)
18. **1:** Impact of Glomerular Filtration Rate on Clinical Outcomes Following Carotid Artery Revascularization in 12,304 Patients from the CARE Registry®. L. Gruberg. [AHA 2010. Oral Presentation.](#)
19. **17:** Clinical referral patterns for carotid artery stenting versus carotid endarterectomy: Results from the CARE registry. R. Longmore. [QCOR 2010. Poster Presentation.](#)
20. **4:** High-risk Features of Carotid Artery Stent Patients: Preliminary Results from the CARE Registry. H.V. Anderson, K. Rosenfield. [ACC 2009. Poster Presentation.](#)
21. **6:** Gender Differences in Short-Term Outcomes After Carotid Revascularization: The CARE Registry. N. Grootenboor. [AHA 2009. Oral Presentation.](#)
22. **13:** Relationship Between Procedure Indications and Outcomes of Carotid Artery Stenting: Preliminary Results from the CARE Registry. K. A. Rosenfield. [AHA 2008.](#)

## Chest Pain - MI Registry™

1. **313:** Characteristics of High-Performing Hospitals for Cardiogenic Shock Following Acute Myocardial Infarction. ACC 2022. Moderated Poster Presentation.
2. **265:** Predicting the Need for Skilled Nursing Facilities After Acute Myocardial Infarction. J. Wasfy. ACC 2018. Poster Presentation.
3. **274:** Association of Pre-Activation of the Cardiac Catheterization Laboratory on Reperfusion Timing Metrics for Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Report from Action Registry®. J. Shavadia. ACC 2018. Moderated Poster Presentation.
4. **178:** Hospital variation in antiplatelet agents after myocardial infarction, an analysis of the NCDR ACTION Registry-GWTG. B. Rodwin. AHA 2018. Moderated Poster Presentation.
5. **232:** Anticoagulation and antiplatelet prescribing trends in chronic kidney disease patients with atrial fibrillation who experience acute myocardial infarction: insights from the ACTION registry. J. Wong. AHA 2018. Poster Presentation.
6. **261:** Association Between Critical Care Unit Utilization and Long-Term Outcomes Among Initially Stable Patients with Non-ST Segment Elevation Myocardial Infarction. A. Fanaroff. AHA 2018. Moderated Poster Presentation.
7. **186:** Temporal Trends in Treatments and Outcomes of Dialysis Patients with Acute Myocardial Infarction: A Report from the National Cardiovascular Data Registry. A. Bagai. ACC 2017.
8. **190:** Hospital variation in targeted temperature management for acute myocardial infarction patients complicated by out-of-hospital cardiac arrest in the U.S. C. Fordyce. ACC 2017. Poster Presentation.
9. **141:** Characteristics of Patients and Hospitals Utilizing Non-Physician Providers for Post-Myocardial Infarction Outpatient Care. J. Rymer. AHA QCOR 2017. Moderated Poster Presentation.
10. **143C:** ICU Utilization in Stable ST-segment Elevation Myocardial Infarction Patients Treated with Rapid Reperfusion: A Report from ACTION Registry. J Shavadia. AHA 2017. Poster Presentation.
11. **196:** Rural Systems of Care: Real World Observations and Trends in STEMI Patient Characteristics, and correlations of arrival mode to outcomes. S. Mikesell. AHA QCOR 2017. Poster Presentation.
12. **205:** Frailty and Mortality in Older Patients with Acute Myocardial Infarction: Observations from the NCDR ACTION Registry-GWTG. Udell. AHA 2017. Poster Presentation.
13. **214:** The Association of Frailty with In-Hospital Bleeding Among Older Adults with Acute Myocardial Infarction: Insights from the Action Registry-GWTG. Dodson. AHA 2017. Poster Presentation.
14. **219:** Cognitive Impairment and In-Hospital Mortality in Older Patients with Acute Myocardial Infarction: A Report from the ACTION Registry – GWTG. Bagai. AHA 2017. Poster Presentation.
15. **122:** Association Between Pre-Catheterization Use of P2Y12 Inhibitors with Timing of CABG, Occurrence of CABG-related Adverse Outcomes and In-hospital Mortality in Patients Presenting with NSTEMI and Requiring Surgical Revascularization: Insights From NCDR. M. Badri. ACC 2016. Poster Presentation.
16. **126:** Association of Acute Myocardial Infarction Cardiac Arrest Patient Volume and In-Hospital Mortality. M. Kontos. ACC 2015.
17. **132:** Hospital-level Variation in the Use of Early Catheterization for Patients with Non-ST elevation Myocardial Infarction: Insights from the NCDR ACTION Registry-GWTG. C. Hansen. ACC 2016. Oral Poster Presentation.
18. **133A:** Contemporary Patterns of Ticagrelor use in Patients with Acute Myocardial Infarction: Insight from the National Cardiovascular Data Registry (NCDR). S. Basra. ACC 2016. Young Investigators Award. Moderated Poster Presentation.
19. **134:** In-hospital mortality of myocardial infarction by sex, age, and obstructive coronary artery disease status in the ACTION Registry-GWTG. N. Smilowitz. ACC 2016. Oral Presentation.



## June 2022

20. **137:** Utilization, Characteristics, and In-Hospital Outcomes for Patients with ST-Elevation Myocardial Infarction Undergoing in Hospital Coronary Artery Bypass Grafting (CABG). Yi Pi. **ACC 2016. Poster Presentation.**
21. **142A:** Ezetimibe use as an adjunct to statin therapy after myocardial infarction: Insights from the ACTION Registry-Get with The Guidelines and Medicare Linked Database. W. Wang. **ACC 2016. Poster Presentation.**
22. **143A:** Intensive Care Unit Utilization Among Patients Over Age 65 with Non-ST-Segment Elevation Myocardial Infarction. A. Fanaroff. **ACC 2016. Oral Presentation.**
23. **101:** Impact of In-Hospital Acute Kidney Injury on Discharge Medications and Long-term Outcomes in Patients presenting with Myocardial Infarction. P. Mody. **AHA 2016. Poster Presentation.**
24. **133B:** Contemporary Patterns of Ticagrelor use in Patients with Acute Myocardial Infarction: Insight from the National Cardiovascular Data Registry (NCDR). S. Basra. **AHA QCOR 2016. Oral Presentation.**
25. **142B:** Post-discharge use of statin and lipid testing after myocardial infarction. W. Wang. **AHA QCOR 2016. Oral Presentation.**
26. **143B:** A risk model to predict need for ICU utilization in patients with NSTEMI. A. Fanaroff. **AHA 2016. Poster Presentation.**
27. **148:** Obesity and Long-Term Outcomes after STEMI in the Elderly: Does the Paradox Extend to Extreme Obesity? Results from the NCDR (National Cardiovascular Data Registry). I. Neeland. **AHA 2016. Oral Presentation.**
28. **156:** Relationship between the CMS 30-day readmission rates for acute myocardial infarction patients and their quality of care and outcomes across NCDR-ACTION/GWTG participating centers. A. Pandey. **AHA 2016. Poster Presentation.**
29. **181:** Does hospital mortality performance for older patients with acute myocardial infarction (AMI) reflect performance for all patients with AMI? K. Dharmarajan. **AHA 2016. Oral Presentation.**
30. **N/A:** Smoking Cessation medication use after acute MI. Padigipati. **AHA 2016. Poster Presentation.**
31. **N/A:** Readmissions After Acute Myocardial Infarction: How Often Do Patients Return to the Discharging Hospital? J. Rymer. **AHA 2016. Poster Presentation.**
32. **158:** Hospital Performance on the NCDR ACTION Registry-GWTG “All-or-None Composite Measure. N. Desai. **ACC 2016. Oral Presentation.**
33. **82:** Post-Hospital Outcomes in Patients with Acute Myocardial Infarction Complicated by Shock: Findings from the ACTION Registry®-GWTGTM. R Shah. **ACC 2015. Poster Presentation.**
34. **83:** The Association of Left Ventricular Ejection Fraction with 1 Year Mortality after Myocardial Infarction: Findings from the ACTION Registry-GWTG Medicare Linked Database. N. Sutton. **ACC 2015. Poster Presentation.**
35. **85:** Revascularization trends in patients with diabetes mellitus and multi-vessel coronary artery disease presenting with non-ST elevation myocardial infarction: Insights from the NCDR®. A. Pandey. **ACC 2015. Oral Presentation.**
36. **95:** The Association of Medicare Part D Enrollment with Outcomes After Acute Myocardial Infarction: An Analysis of Linked ACTION Registry-GWTG and Medicare Data. A. Goyal. **ACC 2015. Poster Presentation.**
37. **180:** Socioeconomic Disparities in Acute Myocardial Infarction Hospital Care in the National Cardiovascular Data Registry. J. Udell. **ACC 2015. Oral Presentation.**
38. **69:** The Association of Electronic Health Record Use with Acute MI Quality of Care and Outcomes: Results from the NCDR®. J. Enriquez. **AHA 2014. Oral Presentation.**
39. **71:** Reperfusion times and in-hospital outcomes among patients with an isolated posterior myocardial infarction: Insights from the NCDR. S. Waldo. **AHA 2014. Oral Presentation.**
40. **72B:** The Association of Home Warfarin Therapy with Acute Treatment Patterns and Bleeding Risk in Patients Presenting with ST-Elevation Myocardial Infarction: Results from the NCDR®. W. Karrowni. **AHA 2014. Poster Presentation.**

## June 2022

41. **73:** Effects of Pre-Hospital ECG Use and Patient Residence Distance from PCI Center on Time to Device Activation in ST Segment Elevation Myocardial Infarction: A Retrospective Analysis from the NCDR. B. Mumma. [AHA 2014. Oral Presentation.](#)
42. **74:** Direct Cath Lab Access Reduced Reperfusion Delays and Mortality for Transferred-in STEMI Patients: Insights from Mission: Lifeline. L. Anderson. [AHA 2014. Poster Presentation.](#)
43. **75:** In-Hospital ADP Receptor Inhibitor Switching in Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry®. A. Bagai. [AHA 2014. Oral Presentation.](#)
44. **76:** The contemporary use of angiography and revascularization among patients with non-ST segment elevation myocardial infarction in the US vs. South Korea. H. Kang. [AHA 2014. Poster Presentation.](#)
45. **43:** Management of Patients with Non-ST Segment Elevation Acute Myocardial Infarction in the United Kingdom, Sweden, and the United States: A Comparison of MINAP/NICOR, SWEDHEART/RIKS-HIA and ACTION Registry-GWTG. R. McNamara. [ACC 2013. Poster Presentation.](#)
46. **57B:** Frequency, Treatment, and Impact of Pre-Hospital Cardiac Arrest among Patients with STEMI: A Report from the ACTION Registry®-GWTG™ and Mission: Lifeline. M. Kontos. [ACC 2013. Poster Presentation.](#)
47. **67:** Frequency and Impact of Prior Myocardial Infarction among Patients with Acute Myocardial Infarction Treated in Contemporary Practice: Results from the NCDR®. L. Shen. [ACC 2013. Poster Presentation.](#)
48. **68:** Rates of Use of Medical Management Across US Hospitals for Patients with Non-ST-Elevation Myocardial Infarction and Multi-Vessel Coronary Artery Disease. R. Harskamp. [ACC 2013. Poster Presentation.](#)
49. **49:** Comparison of Performance Measures and 30-Day Patient Outcomes among Hospitals that Do and Do Not Participate in ACTION Registry- Get with The Guidelines. R. Mathews. [AHA QCOR 2013. Poster Presentation.](#)
50. **70:** Trends in Cardiac Rehabilitation Referral after Myocardial Infarction: Data from the National Cardiovascular Data Registry (NCDR®). A. Beatty. [AHA QCOR 2013. Poster Presentation.](#)
51. **72A:** The Impact of Home Warfarin Therapy on the Management and Outcomes of Patients Presenting with ST-Elevation Myocardial Infarction. R. El Accaoui. [AHA QCOR 2013. Poster Presentation.](#)
52. **50:** Association of Chronic Lung Disease with Treatments and Outcomes of Acute Coronary Syndromes: Results from the NCDR®. J. Enriquez. [AHA QCOR 2012. Poster Presentation.](#)
53. **57A:** Is In-hospital Mortality in ST-elevation Myocardial Infarction Associated with Core Measure Compliance? S. Rennyson. [AHA QCOR 2012. Poster Presentation.](#)
54. **53:** Patient and Neighborhood Factors Associated with Presentation Delay in ST-Elevation Myocardial Infarction: Insights from the NCDR®. A. Miller. [AHA 2012. Poster Presentation.](#)
55. **61:** Incidence, Treatment, and Outcomes of Cardiogenic Shock in STEMI and NSTEMI: Results from ACTION-Registry GWTG. M. Anderson. [AHA QCOR 2012. Poster Presentation.](#)
56. **62:** The Influence of Presenting Electrocardiographic Findings on the Treatment and Outcomes of Patients with Non-ST-elevation Myocardial Infarction (NSTEMI). J. Patel. [AHA 2012. Poster Presentation.](#)
57. **63A:** Impact of Diabetes on Clinical Findings, Management, and In-Hospital Outcomes in Non-ST Elevation and ST Elevation Myocardial Infarction: An Analysis from the NCDR®. R. Pappy. [AHA 2012 Poster Presentation.](#)
58. **63B:** Clinical Characteristics and Outcomes of Patients with Insulin Receiving and Non-Insulin Receiving Diabetes Mellitus Presenting with Myocardial Infarction: An Analysis from The NCDR® ACTION Registry. T. Rousan. [AHA 2012. Poster Presentation.](#)
59. **64:** Association of Hospital Myocardial Infarction Volume with Adherence to ACC/AHA Performance Measures: Insights from the NCDR®. R. Harrison. [AHA 2012. Oral Presentation.](#)
60. **65:** Patterns of Discharge Aspirin Dosing in 213,344 U.S. Patients after Acute Myocardial Infarction: Results from the NCDR®. H. Hall. [AHA 2012. Oral Presentation.](#)
61. **66:** Use of Aldosterone Antagonists at Discharge after Myocardial Infarction: Results from the NCDR®. K. Rao. [AHA 2012. Poster Presentation.](#)

62. **14:** Patterns of Care Among of Patients at High Risk for Ischemic and Bleeding Events after NSTEMI – Insights from the NCDR-ACTION Registry. N. Desai. **ACC 2011. Oral Presentation.**
63. **27:** Characteristics and Management of Cocaine Positive Acute Coronary Syndrome Patients: An Analysis of ACC-NCDR ACTION Registry. N. Gupta. **ACC 2011. Poster Presentation.**
64. **42:** Impact of Society of Chest Pain Centers Accreditation on Quality: An Action Registry Get with the guidelines (ARG) Analysis. F. Peacock. **ACC 2011. Poster Presentation.**
65. **48:** Characteristics and Outcomes of Emergency Department Patients Treated with Thienopyridines: Results from the NCDR®. D. Diercks. **AHA 2011. Oral Presentation.**
66. **51A:** Prevalence of Low Levels of High-Density Lipoprotein Cholesterol (HDL-C) at Presentation in Acute Coronary Syndromes (ACS) and its Relation to In-Hospital Mortality: Results from the NCDR®. Acharjee. **AHA 2011. Oral Presentation.**
67. **51B:** Low Levels of High-Density Lipoprotein Cholesterol (HDL-C) at Presentation in Acute Coronary Syndromes (ACS) and its Relation to Angiographically-Observed Atherosclerotic Burden: Results from the NCDR®. Acharjee. **AHA 2011. Poster Presentation.**
68. **26:** New or presumed new left bundle branch block in patients with acute myocardial infarction: Findings from ACTION Registry-GWTG. K. K. Yeo. **ACC 2010 Poster Presentation.**
69. **44:** Predictors of in-hospital mortality in a contemporary acute myocardial infarction population. M. T. Roe. **ACC 2010. Poster Presentation.**
70. **12:** Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction in the ACTION Registry-GWTG. B. Scirica. **AHA 2010. Poster Presentation.**
71. **21:** Does Increasing Intensity of Anticoagulation Contribute to Bleeding Risk Among NSTEMI Patients on Home Warfarin Therapy? Subherwal. **AHA 2010. Poster Presentation.**
72. **22:** Warfarin Underused at Discharge in High-Risk Atrial Fibrillation following Myocardial Infarction. R. Lopes. **AHA 2010. Poster Presentation.**
73. **25:** The Effects of Patient Characteristics on the Timing of ST-Elevation Myocardial Infarction and Subsequent Response to Therapy. O. Mogabgab. **AHA 2010. Poster Presentation.**
74. **29:** Short-term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury: A Report from the National Cardiovascular Data Registry. C. Fox. **AHA 2010. Oral Presentation.**
75. **31:** Differences in Practice Patterns and Outcomes between Hispanics and Non-Hispanic Whites Treated for ST-Segment Elevation Myocardial Infarction: Results from ACTION Registry – Get with The Guidelines. L. Guzman. **AHA QCOR 2010. Poster Presentation.**
76. **33:** Impact of obesity on the Presentation, treatment, and in-hospital outcomes for 49,329 patients with STEMI in the ACTION-GWTG registry. S. Das. **AHA 2010. Oral Presentation.**
77. **34:** Longer Hospital Length of Stay in Non-ST-Elevation Myocardial Infarction Associated with Higher Risk but Less Evidenced-Based Treatment: Results from ACTION Registry. R. Lopes. **AHA QCOR. 2010 Poster Presentation.**
78. **36:** Characteristics and In-hospital Outcomes of Patients with Non-ST-Segment Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. E. Hanna. **AHA 2010. Poster Presentation.**
79. **38:** In-hospital Outcomes of Anemic Patients Presenting with Non-ST Elevation Myocardial Infarction and Undergoing an Invasive Strategy. E. Hanna. **AHA 2010. Poster Presentation.**
80. **39A:** Hemoglobin A1c and In-hospital Mortality in patients presenting with Acute Coronary Syndromes. V. Aggarwal. **AHA QCOR 2010. Poster Presentation.**
81. **39B:** Comparison of the Prognostic Implications of Peak CK-MB and Troponin Levels Among Patients with Acute Myocardial Infarction. C. T. Chin. **AHA 2010. Poster Presentation.**
82. **40A:** Self Transport versus Emergency Medical Service (EMS) for Patients with STEMI: Updated findings from National Cardiovascular Data Registry ACTION – Get with The Guidelines. R. Mathews. **AHA QCOR 2010. Oral Presentation.**

83. **40B:** Prediction of In-Hospital Major Bleeding Among Patients with Acute Myocardial Infarction: Results From 90,273 Patients in the Acute Coronary Treatment Intervention Outcomes Network Registry®- Get with the Guidelines™ (AR-G). R. Mathews. [AHA QCOR 2010. Poster Presentation.](#)
84. **32:** Comparison of the Prognostic Implications of Peak CK-MB and Troponin Levels Among Patients with Acute Myocardial Infarction. C. T. Chin. [ACC 2010. Poster Presentation.](#)
85. **3:** Antithrombotic Strategy during PCI in NSTEMI: Update from ACTION Registry-GWTG. Alexander. [ACC 2009. Poster Presentation.](#)
86. **7:** Timing of In-Hospital CABG in Relationship to Mortality for ACS Patients: Results from the NCDR ACTION Registry. J. de Lemos. [ACC 2009. Oral Presentation.](#)
87. **11A:** Is Pre-Existing Coronary Disease a Risk Factor for In-Hospital Mortality? An Analysis from The NCDR ACTION-GWTG Registry. M. Kontos. [ACC 2009 Poster Presentation.](#)
88. **11B:** Troponin Positive, MB Negative Patients with Non-ST Elevation Myocardial Infarction: An Under-Treated but High-Risk Patient Group: Results from NCDR ACTION-GWTG Registry. M. Kontos. [ACC 2009. Poster Presentation.](#)
89. **16:** Association of Prior CABG Surgery with early Invasive Therapy in patients with Non-ST Segment Elevation Myocardial Infarction: A Report from the National Cardiovascular Data Registry ACTION Registry-GWTG. M. S. Kim. [ACC 2009. Poster Presentation.](#)
90. **17:** Clopidogrel Use among Medically Managed NSTEMI Patients: Insights from the NCDR ACTION Registry. T. Maddox. [ACC 2009. Oral Presentation.](#)
91. **N/A:** Contemporary Utilization of Antithrombotic Agents among Patients Admitted with Myocardial Infarction in the ACTION Registry-GWTG. B. Scirica. [ACC 2009. Poster Presentation.](#)
92. **4:** Delays in Emergency Department Fibrinolysis as Primary Reperfusion Therapy for Acute ST-elevation Myocardial Infarction. S. Glickman. [AHA 2009. Oral Presentation.](#)
93. **20:** Evaluation of Door-In-Door-Out Time as a Clinical Performance Measure for Patients Transferred for Primary Percutaneous Coronary Intervention. H. Ting. [AHA 2009. Oral Presentation.](#)
94. **15:** Quality of Antithrombotic Management Among STEMI Patients Transferred for Primary Percutaneous Coronary Intervention. T. Wang. [QCOR 2009. Poster Presentation.](#)
95. **2:** Decline in the Use of Drug-Eluting Stents for Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention - Results from the CRUSADE and ACTION Registries. M. Roe. [ACC 2008.](#)
96. **6:** Short-term Outcomes of STEMI and NSTEMI in Patients with Chronic Kidney Disease: A Report from the National Cardiovascular Data ACTION Registry. C. Fox. [ACC 2008.](#)
97. **8:** The Impact of Prior Stroke on the Use of Evidence-based Therapies, and In-Hospital Outcomes in MI Patients: A Report of the NCDR ACTION GWTG Registry. F. Abtahian. [ACC 2008.](#)
98. **9:** Time from Symptom Onset to Hospital Presentation in Women with Myocardial Infarction: A temporal analysis from the CRUSADE and NCDR ACTION Registry. D. Diercks. [ACC 2008.](#)
99. **10:** Early use of beta-blockers (BB) is a quality indicator for the treatment of patients (pts) with ST-segment elevation (STEMI) and non-ST-segment myocardial infarction (NSTEMI), despite limited randomized clinical trials data. However, data from the recent COMMIT trial found an early hazard with BBs in this setting, especially for pts with high-risk features. Kontos. [ACC 2008.](#)
100. **19:** STEMI Care and Outcomes for the Oldest-Old: Update from NCDR ACTION Registry-GWTG. Forman. [ACC 2009. Poster Presentation.](#)
101. **N/A:** Limitations of Using Cardiac Catheterization Rates as a Quality Measure for Non-ST-Segment Elevation Myocardial Infarction. Garracholou. [ACC 2009. Poster Presentation.](#)
102. **1:** Prehospital ECGs May Shorten ED Length of Stay, But Do Not Improve the Process of Emergency Department Care in NSTEMI Patients. M. Cudnik. [AHA 2008.](#)

June 2022

## Diabetes Collaborative Registry®

1. **9:** Understanding the Contemporary Use of Thiazolidinediones. An Analysis of the Diabetes Collaborative Registry. S. Arnold. [ESC HF 2019](#).
2. **19:** Eligibility Varies Across the 3 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Outcomes Trials Among Adults with Type 2 Diabetes: Implications from Analysis of the Diabetes Collaborative Registry. E. Wittbrodt. [ACC 2018](#). [Poster Presentation](#).
3. **21:** Real-World Opportunity of Empagliflozin in Cardiovascular Risk Factor Modification: An NCDR® “Research-to-Practice” Project from the Diabetes Collaborative Registry (DCR). S. Arnold. [ACC 2018](#). [Poster Presentation](#).
4. **4:** Composite Cardiovascular Risk Factor Target Achievement and its Indicators in US Adults with Diabetes: The Diabetes Collaborative Registry. N. Wong. [ADA 2018](#). [Poster Presentation](#).
5. **29:** Second Line Glucose-Lowering Treatment Therapies as Chosen by Cardiologists Versus Non-Cardiologists: An Analysis of the Diabetes Collaborative Registry (DCR). Repetto. [EASD 2018](#). [Oral Presentation](#).
6. **N/A:** Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-world Impact of the LEADER Trial on Improving Cardiovascular Outcomes in Patients with Diabetes at High Cardiovascular Risk. S. Arnold. [ACC 2017](#). [Oral Presentation](#).
7. **N/A:** Describing the Cardio-Renal-Metabolic Patient within the Diabetes Collaborative Registry. LoCasale. [ADA 2017](#). [Oral Presentation](#).
8. **24:** Patterns of glucose-lowering medication use in patients with diabetes and heart failure: insights from the Diabetes Collaborative Registry (DCR). S. Arnold. [EASD 2017](#). [Poster Presentation](#).
9. **N/A:** Management of Patients with Diabetes and Heart Failure with Reduced Ejection Fraction: A Cross-Country Comparison. S. Arnold. [IDF 2017](#). [Poster Presentation](#).
10. **N/A:** Assessing the Personalization of Glycemic Management Strategies Through the Diabetes Collaborative Registry (DCR). S. Arnold. [AHA QCOR 2017](#). [Oral Presentation](#).
11. **N/A:** Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-world Impact of the IRIS Trial on Improving Outcomes in Patients with Cerebrovascular Disease. S. Arnold. [QCOR 2017](#). [Poster Presentation](#).
12. **N/A:** Characteristics of the Diabetes Collaborative Registry®: A New Resource for Diabetes Research and Quality Improvement. S. Arnold. [ADA 2016](#). [Poster Presentation](#).
13. **N/A:** Quality of care of the initial patient cohort of the Diabetes Collaborative Registry. S. Arnold. [ADA 2016](#). [Oral Presentation](#).
14. **N/A:** Defining the potential impact of the EMPA-REG OUTCOMES® trial on improving cardiovascular outcomes of patients in the Diabetes Collaborative Registry. Arnold. [EASD 2016](#). [Oral Presentation](#).

June 2022

## EP Device Implant Registry™ (formerly ICD)

1. **248:** Outcomes of patients with recalled defibrillator leads: Results from the NCDR-ICD Registry. Zeitler. [AHA 2020](#).
2. **151:** Longitudinal Outcomes After Implantation of a Subcutaneous or Transvenous ICD: A Report from the NCDR. Friedman. [HRS 2020](#).
3. **120:** Outcomes from ICD generator replacements in response to FDA recalls. E. Zeitler. [ACC 2019](#).
4. **167:** Survival Following Implantable Cardioverter-Defibrillator Implantation in Patients with Cardiac Amyloidosis. A. Annapureddy. [ACC 2019](#).
5. **184:** Use and Outcomes of Dual Chamber and CRT defibrillators among older patients undergoing ICD implantation with a ventricular pacing indication: An Analysis from the NCDR ICD Registry. R. Borne. [ACC 2019](#).
6. **211:** Implantable Cardioverter Defibrillator in Patients with Non-ischemic Cardiomyopathy in the United States – Insights from the NCDR ICD Registry. V. Kutyla. [ACC 2019](#).
7. **239:** Survival Following Implantable Cardioverter-Defibrillator Implantation in Patients with Cardiac Sarcoidosis. A. Annapureddy. [ACC 2019](#).
8. **218:** Longitudinal Outcomes Associated with Non-Evidence-Based ICD Implantations Among Medicare Beneficiaries: A Report from the National Cardiovascular Data Registry. Daimee. [AHA 2019](#).
9. **186:** Survival after ICD Generator Changes in the NCDR ICD Registry and Improvement in Left Ventricular Ejection Fraction Relative to the Initial Primary Prevention Implant. Bilchick. [AHA 2019](#).
10. **190:** Access and Utilization effects of the Affordable Care Act on ICD Therapy: Findings from NCDR. Madias. [HRS 2019](#).
11. **173:** Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Dialysis Patients: A report from the National Cardiovascular Data Registry. P. Pun. [HRS 2019](#).
12. **168:** Sex Differences in Adverse Events from Subcutaneous Implantable Cardioverter-Defibrillator Implantation. S. Dhruva. [HRS 2019](#).
13. **202:** Outcomes After Implantable Cardioverter-Defibrillator Implantation in Patients with Ischemic and Non-ischemic Cardiomyopathies. A. Higgins. [HRS 2019](#).
14. **137:** Outcomes Among Medicare Beneficiary Patients with Nonspecific Intraventricular Conduction Delay versus Right Bundle Branch Block Implanted with Cardiac Resynchronization Therapy with Defibrillator: Insights from the National Cardiovascular Data Registry. Kawata. [ACC 2018](#). [Poster Presentation](#).
15. **146:** Characteristics and Outcome of Pediatric Patients Who Undergo Placement of Implantable Cardioverter-Defibrillator - An Insight from the National Cardiovascular Data Registry (NCDR). Baskar. [ACC 2018](#). [Poster Presentation](#).
16. **72:** Outcomes Among Medicare Beneficiaries are Optimized When Primary ICD Implant Occurs During an Elective Rather Than Unplanned Hospitalization. G. Stewart. [AHA 2018](#). [Poster Presentation](#).
17. **104C:** Survival Benefit from the Resynchronization and Defibrillator Components of Cardiac Resynchronization Therapy Defibrillators in the NCDR ICD Registry. Bilchick. [AHA 2018](#). [Oral Presentation](#).
18. **107A:** Association Between Industry Payments and In-Hospital Procedure-Related Complication Rates Following ICD Implantation: Results from the NCDR ICD Registry. Henien. [AHA 2018](#). [Poster Presentation](#).
19. **107B:** Association Between Industry Payments to Physicians and Device Selection: A Report from the NCDR ICD Registry. A. Annapureddy. [AHA 2018](#). [Poster Presentation](#).
20. **184:** Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice: An Analysis of the National Cardiovascular Data ICD Registry. R. Borne. [AHA 2018](#).

## June 2022

21. **185:** Defibrillation Safety Margin Testing in Congenital Heart Disease Patients with Implantable-Cardioverter Defibrillators: Results from the National Cardiovascular Data Registry ICD Registry. Prutkin. [AHA 2018. Poster Presentation.](#)
22. **226:** Defibrillation Safety Margin Testing in Pediatric Patients with Implantable-Cardioverter Defibrillators: Insights from the National Cardiovascular Data Registry ICD Registry. J. Prutkin. [AHA 2018. Poster Presentation.](#)
23. **162:** Periprocedural Risk and Survival after ICD Placement in Patients with Advanced Heart Failure. Fudim. [Heart Failure Society of America 2018.](#)
24. **136:** Quadripolar vs. Bipolar Left Ventricular Leads in Cardiac Resynchronization Therapy: An Analysis from the NCDR. Hakemi. [ACC 2017. Poster Presentation.](#)
25. **128:** Outcomes Following Implantable Cardioverter-Defibrillator Generator Replacement in Patients with Recovered Left Ventricular Systolic Function: Insights From the NCDR. Thomas. [AHA 2017. Poster Presentation.](#)
26. **151:** Predictors of an Insufficient Defibrillation Testing Safety Margin Among Patients Implanted with a Subcutaneous Implantable Cardioverter Defibrillator: A Report from the National Cardiovascular Data Registry. Friedman. [AHA 2017. Oral Presentation.](#)
27. **158:** Predictors of Performing Defibrillation Testing Among Patients Implanted with a Subcutaneous Implantable Cardioverter Defibrillator: A Report from the National Cardiovascular Data Registry. Friedman. [AHA 2017. Poster Presentation.](#)
28. **186:** Gender Differences in Survival with Cardiac Resynchronization Therapy Defibrillators in the NCDR ICD Registry. Bilchick. [AHA 2017. Poster Presentation.](#)
29. **101:** Early use of the subcutaneous implantable cardioverter defibrillator in the United States: A report from the National Cardiovascular Data Registry. D. Friedman. [ACC 2016. Oral Presentation.](#)
30. **104B:** Medicare Primary Prevention ICD Survival Outcomes Based on the Seattle Proportional Risk Model and the Seattle Heart Failure Model. K. Bilchick. [AHA 2016. Oral Presentation.](#)
31. **104A:** Medicare Primary Prevention ICD Survival Outcomes Based on the Seattle Proportional Risk Model and the Seattle Heart Failure Model. K. Bilchick. [HRS 2016. Oral Presentation.](#)
32. **109:** Process of Care and Outcomes in the Uninsured: Insight from the NCDR ICD Registry. I. Ahmed. [HRS 2016. Poster Presentation.](#)
33. **121:** The Association Between Prolonged PR Interval, QRS Characteristics, and Outcomes Among Patients Undergoing CRT: A Report from the NCDR. D. Friedman. [HRS 2016. Oral Presentation.](#)
34. **149:** Use of Hemodynamic Remote Patient Monitoring Among Patients with Implantable Defibrillators and its Association with Mortality and Rehospitalization. J. Akar. [HRS 2016. Poster Presentation.](#)
35. **167:** Patient Centered Outcomes of Implantable Defibrillator Therapy in Older Patients. D. Kramer. [QCOR 2016. Oral Presentation.](#)
36. **79:** Comparative Effectiveness of Cardiac Resynchronization Therapy with Defibrillator versus Defibrillator Alone in Heart Failure Patients with Moderate to Severe Chronic Kidney Disease. D. Friedman. [ACC 2015. Poster Presentation.](#)
37. **83:** Temporal Trends in and Factors Associated with Single Versus Dual Coil Implantable Cardioverter-Defibrillator Leads: Data from the NCDR ICD Registry. Pokorney. [ACC 2015. Poster Presentation.](#)
38. **88B:** Variations in Use of Remote Monitoring of Implantable Defibrillators Relative to the Introduction of Billing Codes Specific to Remote Monitoring. F. Altaf. [ACC 2015. Poster Presentation.](#)
39. **28:** Age Differences in Adherence to Guidelines among Patients Receiving Implantable Cardioverter-Defibrillators for Primary Prevention in the United States. D. Kaiser. [HRS 2015. Poster Presentation.](#)
40. **73:** Implantable Cardioverter Defibrillators in Adults with Congenital Heart Disease: Insights from the NCDR®. M. Gleva. [HRS 2015. Poster Presentation.](#)

## June 2022

41. **94:** Implantable Cardioverter-Clinical Characteristics and Survival in Patients Receiving Implantable Defibrillators for Secondary Prevention of Sudden Cardiac Death in Contemporary Practice - An Analysis from the NCDR ICD Registry. D. Katz. [HRS 2015. Poster Presentation.](#)
42. **96:** Outcomes of Older Survivors of Sudden Cardiac Death Receiving Secondary Prevention Implantable Cardioverter Defibrillators - An Analysis from the NCDR ICD Registry. J. Betz. [QCOR 2015. Never presented because conference was canceled.](#)
43. **59B:** Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving Cardiac Resynchronization Therapy: Results from the NCDR®. R. Zusterzeel. [ACC 2014. Poster Presentation.](#)
44. **62A:** Non-trans venous Lead Implantation in Pediatric and Congenital Heart Disease Patients: Early Analysis from the NCDR-ICD Registry. C. Berul. [ACC 2014. Poster Presentation.](#)
45. **62B:** Implant and Clinical Characteristics for Primary versus Secondary Prevention Indications for Pediatric and Congenital Heart Patients in the NCDR ICD Registry. C. Berul. [ACC 2014. Poster Presentation.](#)
46. **75:** Use and Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients with Heart Failure and Atrial Fibrillation: Data from the NCDR-ICD Registry. P. Khazanie. [ACC 2014. Poster Presentation.](#)
47. **59A:** Women have Better Survival than Men with Cardiac Resynchronization Therapy in Left Bundle Branch Block: An Observational Comparative Effectiveness Study from the National Cardiovascular Data Registry. R. Zusterzeel. [AHA 2014. Oral Presentation.](#)
48. **63:** Incidence and Predictors of Peri-Procedural Complications with Trans venous Lead Extractions in the Real World: Data from NCDR ICD Registry. N. Sood. [AHA 2014. Poster Presentation.](#)
49. **78:** Long-Term Device-Related Adverse Events After Implantable Cardioverter-Defibrillator Therapy. I. Ranasinghe. [AHA 2014. Poster Presentation.](#)
50. **49:** Cardiac Resynchronization Therapy in the Elderly. Heidenreich. [ACC 2013. Poster Presentation.](#)
51. **57C:** Cardiac Perforation from Implantable Cardioverter-Defibrillator Lead Placement and In-Hospital Adverse Events and Mortality: Insights from the NCDR®. J. Hsu. [ACC 2013. Oral Presentation.](#)
52. **66:** Building a risk model from the NCDR ICD registry for in-hospital adverse outcomes following ICD implantation. J. Dodson. [ACC 2013. Poster Presentation.](#)
53. **23:** Antithrombotic therapy and outcomes after ICD implantation: An Analysis from the Linked NCDR-CMS Claims Database. H. Ghanbari. [AHA 2013. Poster Presentation.](#)
54. **52:** Clinical Effectiveness of Cardiac Resynchronization Therapy Compared to Medical Therapy Alone Among Patients with Heart Failure: An Analysis of the ICD and ADHERE National Registries. P. Khazanie. [AHA 2013. Poster Presentation.](#)
55. **71A:** Do ICDs Prevent Hip Fractures or Are Physicians Selecting Appropriate Candidates for ICDs? S. Setoguchi. [AHA 2013. Oral Presentation.](#)
56. **71B:** Real-World Effectiveness of ICDs Implanted during Unplanned Medicare Hospitalizations. C. Chen. [AHA 2013. Oral Presentation.](#)
57. **71C:** Outcomes among Medicare beneficiaries are optimized when primary ICD implant occurs during an elective rather than unplanned hospitalization. G. Stewart. [AHA 2013. Oral Presentation.](#)
58. **44:** Degree of Utilization of ICD Remote Patient Monitoring and Determinants of Activation. J. Akar. [HRS 2013. Poster Presentation.](#)
59. **50:** Rates and Predictors of Implantable Cardioverter-Defibrillator Infection in 201,836 Medicare Patients: Results from the NCDR®. J. Prutkin. [HRS 2013. Oral Presentation.](#)
60. **57A:** Weekend and Afternoon/Evening Implantable Cardioverter-Defibrillator Implant Procedures Are Associated with Increased Adverse Events and Mortality: Insights from the NCDR®. J. Hsu. [HRS 2013. Oral Presentation.](#)
61. **57B:** Coronary Sinus Dissection from Cardiac Resynchronization Therapy Implantation and Associated In-Hospital Adverse Events: Insights from the NCDR®. J. Hsu. [HRS 2013. Poster Presentation.](#)



## June 2022

62. **61:** Temporal Trends in Patient Characteristics and Outcomes Among Medicare Beneficiaries Undergoing Primary Prevention ICD Implantation in The United States: 2006 to 2010: Results from the NCDR. R. Borne. [QCOR 2013. Poster Presentation.](#)
63. **40:** Temporal Trends in Quality of Care among ICD Recipients: Insights from the NCDR ICD Registry. J. Dodson. [ACC 2012. Oral Presentation.](#)
64. **41:** Low Body Mass Index is Associated with In-Hospital Adverse Events and Mortality Among Implantable Cardioverter-Defibrillator Recipients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J. Hsu. [ACC 2012. Poster Presentation.](#)
65. **42:** Contemporary Patterns of Practice and Characteristics of Patients Undergoing Defibrillation Testing Versus Those Who Do Not Undergo Testing at the Time of Initial Implantable Cardioverter Implantation: Analysis of the NCDR ICD Registry. A. Russo. [ACC 2012. Poster Presentation.](#)
66. **69:** Development of Composite Performance Measures for Discharge Medication Prescribing for Patients undergoing PCI or ICD Implant Procedures. F. Masoudi. [ACC 2012. Poster Presentation.](#)
67. **42:** Factors Predicting High Defibrillation Energy Requirements: Analysis of the NCDR ICD Registry. A. Russo. [AHA 2012. Oral Presentation.](#)
68. **46:** Impact of Gender on Intermediate-Term Outcome of Patients with Single or Dual Chamber Cardioverter Defibrillators Implanted for Primary Prevention: Analysis of the NCDR ICD Registry. A. Russo. [AHA 2012. Oral Presentation.](#)
69. **58:** Prevalence and Temporal Trends of Antiarrhythmic Use among ICD Recipients: Findings from the NCDR® ICD Registry. S. Dev. [AHA 2012. Poster Presentation.](#)
70. **45A:** Lead Revision is Associated with Increased Complications in Patients Undergoing Implantable Cardioverter-Defibrillator Implantation. S. Wei. [HRS 2012. Poster Presentation.](#)
71. **45B:** Prevalence and Predictors of Cardiac Perforation in Implantable Cardioverter- Defibrillator Implantation. S. Wei. [HRS 2012. Oral Presentation.](#)
72. **47:** Outcomes of Single and Dual Chamber ICDs for Primary Prevention of Sudden Cardiac Death. P. Peterson. [QCOR 2012. Poster Presentation.](#)
73. **39:** Is Cardiac Resynchronization Therapy Use Improving Among Racial/Ethnic Minorities? An analysis of 107,096 patients from the NCDR-ICD registry. Z. Eapin. [AHA 2011. Poster Presentation.](#)
74. **41A:** Low Body Mass Index is Associated with In-Hospital Adverse Events and Mortality Among Implantable Cardioverter-Defibrillator Recipients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J. Hsu. [Bay Area Research Symposium 2011. Poster Presentation.](#)
75. **41B:** Effect of Body Mass Index on Cardiac Resynchronization Therapy Intention and Success: A Report from the NCDR Implantable Cardioverter-Defibrillator Registry. J. Hsu. [Bay Area Research Symposium 2011. Poster Presentation.](#)
76. **6:** Physician Procedure Volume and Complications of Cardioverter-Defibrillator Implantation from the ICD Registry™. J. Freeman. [QCOR 2011. Poster Presentation.](#)
77. **5:** The Relation between Hospital Procedure Volume and Complications of Cardioverter-Defibrillator Implantation from the National Cardiovascular Data Registry. M. Hlatky. [ACC 2010. Oral Presentation.](#)
78. **24:** Blood Pressure, BUN, Creatinine, Congestive Heart Failure and Cardiac Arrest (B2C3 Score) Predicts Procedure Mortality for Elective ICD Implantation: Data from the ICD Registry (TM). D. Haines. [ACC 2010. Poster Presentation.](#)
79. **35:** Impact of the Medtronic Fidelis lead recall on utilization of implantable cardioverter defibrillators: Data from the NCDR ICD Registry. P. Bhatt. [ACC 2010. Poster Presentation.](#)
80. **32:** The Use of Electrophysiology Studies in the Post-AVID and Post-SCD-HeFT Era: Data from the NCDR® ICD Registry™. A. Cheng. [AHA 2010. Oral Presentation.](#)
81. **37:** Optimal medical therapy uses among implantable cardioverter-defibrillator recipients: insights from the NCDR ICD Registry. A. Miller. [AHA 2010. Oral Presentation.](#)

## June 2022

82. **8:** Prevalence of non-evidence-based ICD implantations in the United States: Results from the NCDR-ICD Registry. S. Al-Khatib. [HRS 2010. Oral Presentation.](#)
83. **19:** Distribution of Risk and Potential Benefit of ICDs among primary prevention patients in the U.S. V. Tsai. [NRSA 2010. Poster Presentation.](#)
84. **20A:** Regional Variations in Physicians' Attitudes Towards Implantable Cardioverter-Defibrillators. D. Matlock. [QCOR 2010. Poster Presentation.](#)
85. **20B:** What is More Important in Cardiologists' Decision Making Around Implantable-Cardioverter Defibrillators (ICD), Mortality Data or Patient Preferences? D. Matlock. [QCOR 2010. Poster Presentation.](#)
86. **36:** Discretionary Use of Dual Lead Implantable Cardioverter-Defibrillators (ICDs) by Hospitals. D. Matlock. [QCOR 2010. Poster Presentation.](#)
87. **17:** Regional Variations of Primary Prevention Implantable Cardioverter-Defibrillators: Results from the National Cardiovascular Data Registry (NCDR). Matlock, Masoudi. [ACC 2009. Oral Presentation.](#)
88. **18:** Clinical Characteristics of Patients with End Stage Renal Disease on Dialysis Referred for Implantable Cardioverter Defibrillator Implantation. A. Aggarwal. [ACC 2009. Oral Presentation.](#)
89. **2:** Factors Influencing the Use of Higher-Tech/Higher Cost Implantable Cardioverter-Defibrillators: Data from the NCDR ICD Registry. R. Lampert. [AHA 2009. Poster Presentation.](#)
90. **22:** Prevalence and Predictors of "Off-label" use of Cardiac Resynchronization Therapy in Patients Enrolled in the NCDR ICD Registry. M. Reynolds. [AHA 2009. Poster Presentation.](#)
91. **23:** ICD Implant-Related Bleeding in the Era of Dual Antiplatelet Therapy. W. Maisel. [AHA 2009. Oral Presentation.](#)
92. **30:** Acute Lead Dislodgements in Patient Undergoing ICD and CRT Implants. A. Cheng. [AHA 2009. Oral Presentation.](#)
93. **31:** System Level Contributions to Disparities in Cardiac Resynchronization Therapy with Defibrillator in the ACC/NCDR ICD Registry. S. Farmer. [QCOR 2009.](#)
94. **7A:** Curtis: Association of physician certification with rates of CRT-D implantation in patients eligible for CRT-D therapy: Insights from the NCDR ICD Registry. J. Curtis. [AHA 2008.](#)
95. **7B:** Association of implanting physician certification with complications following implantable cardioverter-defibrillator procedures: Insights from the NCDR ICD Registry. J. Leubbert. [AHA 2008.](#)
96. **16:** Dual chamber ICD selection is associated with racial and socioeconomic disparities and increased complication rates among patients enrolled in the ACC-NCDR ICD Registry. T. Dewland. [AHA 2008.](#)
97. **1:** Racial and Ethnic Differences in Nationwide Utilization of Cardiac Resynchronization Therapy. S. A. Farmer. [AHA 2007.](#)
98. **3:** Differences in Implantation-Related Complications between Men and Women Receiving ICD Therapy for Primary Prevention. P. N. Peterson. [AHA 2007.](#)
99. **4:** Sex Differences in the Characteristics of Patients Receiving ICD Therapy for Primary Prevention. S. L. Daugherty. [AHA 2007.](#)
100. **8A:** Patients Who Receive an Implantable Cardioverter Defibrillator for MADIT-II Criteria in Clinical Practice are Different from Patients Enrolled in MADIT-II. S. Al-Khatib. [AHA 2007. Oral Presentation.](#)
101. **8B:** Do Patients Who Meet SCD-HeFT Criteria in Clinical Practice Differ from Patients Enrolled in SCD-HeFT? S. Al-Khatib. [AHA 2007. Oral Presentation.](#)

June 2022

## IMPACT Registry®

1. **34:** Use of Transcatheter Pulmonary Valve Replacement Across the Age Span of Patients with Congenital Heart Disease- a Report from the NCDR IMPACT Registry. Ada Stefanescu Schmidt. **ACC 2019. Oral Presentation.**
2. **16:** Evaluation of Failure to Rescue as Quality Metric in Pediatric Cardiac Catheterization: Analysis of the IMPACT Registry. Michael O'Byrne. **ACC 2017. Poster Presentation,**
3. **24:** Risk of catastrophic outcome following cardiac catheterization for pulmonary hypertension: An analysis of data from the IMPACT® Registry. M. O'Byrne. **ACC 2017. Moderated Poster.**
4. **18A:** Variations in practice patterns in device closure of atrial septal defects and patent ductus arteriosus: An analysis of data from the IMPACT® Registry. M. O'Byrne. **AHA 2016. Rapid Fire Moderated Poster.**
5. **18B:** Variability in Practice Patterns and Consistency with Published Guidelines for Aortic and Pulmonary Balloon Valvuloplasty: An Analysis of Data from the IMPACT Registry. A. Glatz. **AHA 2016. Rapid Fire Moderated Poster.**
6. **5B:** Adjusting for Risk Associated with Congenital Cardiac Catheterization: A Report from the IMPACT® Registry. N. Jayaram. **CHOP 2016. Poster Presentation.**
7. **14:** Risk factors for adverse events after catheter-based procedures in adolescents and adults with congenital heart disease - a report from the IMPACT registry. A. Stefanescu. **ESC 2016. Poster Presentation.**
8. **9:** Efficacy of Proximal Pulmonary Artery Stenting: Rates of Procedural Success and Complications by Procedural Indication. M. Lewis. **ACC 2015. Moderated Poster Presentation.**
9. **11:** Deficient retro-aortic rim and other predictors of peri-procedural outcomes following device closure of atrial septal defects. M. O'Byrne. **ACC 2015. Oral Presentation.**
10. **5A:** Adjusting for Risk Associated with Congenital Cardiac Catheterization: A Report from the IMPACT® Registry. N. Jayaram. **AHA 2014. Poster Presentation.**
11. **8:** Relationship Between Hospital Procedure Volume and Complications Following Congenital Cardiac Catheterization: A Report from the IMPACT® Registry. N. Jayaram. **AHA 2014. Poster Presentation.**
12. **1B:** The IMPACT Registry (Improving Pediatric and Adult Congenital Treatment): Update and Trends. R. Vincent. **ACC 2013. Poster Presentation.**
13. **3A:** First Review of Community Practice with respect to Aortic and Pulmonary Artery Stenting. J. Moore. **ACC 2013. Poster Presentation.**
14. **3B:** First Review of Community Practice with respect to Device Closure of ASD and PDA. J. Moore. **ACC 2013. Poster Presentation.**
15. **3C:** First Review of Community Practice with respect to Aortic and Pulmonary Valvuloplasty. J. Moore. **ACC 2013. Poster Presentation.**
16. **N/A:** IMPACT Registry™: Review of the Registry's First Year. G. Martin. **ACC 2012. Oral Presentation.**
17. **18C:** Improving Pediatric and Adult Congenital Treatment. J. Rome. **World Congress of Pediatric Cardiology & Cardiac Surgery (June 2009). Oral Presentation.**
18. **1A:** IMPACT Registry™: Improving pediatric and Adult Congenital Treatment. G. Martin. **NICHU 8<sup>th</sup> Annual Forum for Improving Children's Health Care (March 2009). Poster Presentation.**
19. **23:** Percutaneous Patent Ductus Arteriosus (PDA) Closure Among Infants <6kg: A NCDR® Study. C. Backes. **PAS Conference 2009. Moderated Poster.**
20. **29:** Trainee Presence in the Cardiac Catheterization Laboratory and Association with Procedural Outcomes Following Pediatric Cardiac Catheterization. N. Jayaram **CHOP. Poster Presentation.**

**June 2022**  
**LAAO Registry™**

1. **61:** Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report from The NCDR LAAO Registry. [ACC 2022. Poster Presentation.](#)
2. **80:** 1-Year Clinical Outcomes Following Watchman Transcatheter LAAO For Stroke Prevention In Patients With Atrial Fibrillation: A Report From The NCDR LAAO Registry. [ACC 2021. Oral Presentation.](#)
3. **46:** Gender Differences in Outcomes with Patients Undergoing Percutaneous Left Atrial Appendage Occlusion: Insights from the NCDR LAAO Registry. D. Darden. [AHA 2020. Poster Presentation.](#)

**June 2022**  
**PINNACLE Registry®**

1. **140:** Association Between Accountable Care Organization Participation and Quality of Outpatient Cardiovascular Care. **ACC 2022. Poster Presentation.**
2. **213:** The 2017 Acc/Aha Hypertension Guidelines and Cha2ds2-Vasc Up-Scoring in Patients With Atrial Fibrillation: Insights From The NCDR® Pinnacle® Registry. **ACC 2022. Moderated Poster.**
3. **196:** Is Appropriate Use of Oral Anticoagulants Improving Among Atrial Fibrillation Patients? Results From the Benchmarking an Oral Anticoagulant Treatment Rate in Patients with Nonvalvular Atrial Fibrillation (Boat-AF) Study and Comparison To 387,975 Participants in The Pinnacle Registry®. **ACC 2021. Poster Presentation.**
4. **188:** Relationship Between Industry Payments to Physicians and Prescription Patterns for NOACs, PCSK9 inhibitors, and ARNI: A Report from the NCDR PINNACLE Registry. **AHA 2020.**
5. **198:** Association Between Cardiovascular Event Type and Smoking Cessation Rates Among Outpatients with Atherosclerotic Cardiovascular Disease: Insights from the NCDR PINNACLE Registry. **AHA Epi Lifestyle 2020.**
6. **169:** Influence of Neighborhood Income on Variations in Coronary Artery Disease Secondary Prevention Care Among Outpatient Cardiology Practices. **ACC 2019.**
7. **180:** Relevance and Significance of Left Ventricular Ejection Fraction in Chronic Heart Failure Phenotypes in Patients with Heart Failure with Preserved, Midrange and Reduced Ejection Fraction: Results from the PINNACLE Registry. **ACC 2019.**
8. **218:** Baseline Assessment of the Current Management of Patients with ASCVD in the PINNACLE Registry. **AHA 2019.**
9. **106:** Effect of Oral Anticoagulation Use on Thromboembolic Risk and Bleeding in Women Compared with Men with Atrial Fibrillation: Findings from the PINNACLE Data Registry. **AHA 2019.**
10. **154:** Association between neighborhood socioeconomic status and quality of outpatient cardiovascular care in the PINNACLE registry. **AHA 2019.**
11. **172:** Advance Care Planning and Prognosis Education in Patients with Heart Failure: Insights from the NCDR PINNACLE Registry. **AHA 2019.**
12. **205:** Variations in Quality Measure Compliance in Prescriptions for Atrial Fibrillation Patients Among Outpatient Cardiology Practices: Insights from the NCDR PINNACLE Registry®. **HRS 2019.**
13. **95:** Management of Resistant Hypertension and Implications of PATHWAY-2 Trial in US Cardiology Practices: Insights from NCDR PINNACLE Registry. **ACC 2018.**
14. **131:** Reducing Cardiovascular Risk in the Medicare Million Hearts Risk Reduction Model. B. Borden. **ACC 2018. Moderated Poster.**
15. **136:** Guideline- recommended patient education among outpatients with heart failure. K. Minges. **ACC 2018. Moderated Poster.**
16. **158:** Patient and Practice Characteristics Associated with Switching from Warfarin to a Direct Oral Anticoagulants in Patients with Atrial Fibrillation – An Analysis from the NCDR PINNACLE Registry. C. Sciria. **AHA 2018. Poster Presentation.**
17. **196:** The Benchmarking an Oral Anticoagulant Treatment Rate in Patients with Nonvalvular Atrial Fibrillation (BOAT-AF) study: A prospective, multicenter study evaluating perspectives on use of oral anticoagulation using a patient survey and clinical review by the treating physician among patients not currently treated with oral anticoagulation. **AHA 2018.**

## June 2022

18. **90:** Implications of the IMPROVE-IT Trial for Contemporary Cardiovascular Practice: An NCDR® Research to Practice (R2P) Project. T. Maddox. [ACC 2017. Poster Presentation.](#)
19. **93A:** Implications of the FDA approval of PCSK9 inhibitors for Contemporary Cardiovascular Practice: Findings from the NCDR® Research to Practice (R2P) Initiative. P. Hess. [ACC 2017. Poster Presentation.](#)
20. **93B:** Implications of the Dual-Antiplatelet Therapy (DAPT) Study: Insights from the NCDR Research to Practice Initiative. Sandhu. [ACC 2017. Poster Presentation.](#)
21. Implications of the LEGACY Trial of Weight Loss for Atrial Fibrillation in US Cardiovascular Practice: An NCDR PINNACLE Research to Practice (R2P) Project. [ACC 2017.](#)
22. **74:** Disparities and geographic variation in the treatment of atrial fibrillation in Native Americans enrolled in the ACC PINNACLE AF registry. [AHA 2017.](#)
23. **103A:** Practice-level Variation in Smoking Cessation Assistance Provided in the Cardiology Clinics: Insights from the NCDR PINNACLE Registry. Sardana. [AHA 2017. Poster Presentation.](#)
24. **103B:** Association of Neighborhood Socioeconomic Status with Smoking Cessation Assistance Provided in the Cardiology Practices: Insights from the NCDR PINNACLE Registry. Sardana. [AHA 2017. Poster Presentation.](#)
25. **119:** Cardiovascular Secondary Prevention Therapies are Under prescribed in Patients with Peripheral Artery Disease: Findings from the NCDR PINNACLE Registry. [AHA 2017.](#)
26. **77:** Association of Insurance Type with Receipt of Oral Anticoagulation in Atrial Fibrillation: An Analysis of the American College of Cardiology NCDR PINNACLE Registry. C. Yong. [ACC 2016. Poster Presentation.](#)
27. **83:** Comparison of major bleeding risk in outpatients with atrial fibrillation on oral anticoagulants: data from the NCDR PINNACLE registry. J. Wong. [ACC 2016. Oral Presentation.](#)
28. **14:** Practice Level Variation in the Prescription of Direct Oral Anticoagulants: Insights from the NCDR PINNACLE Registry. L. Marzec. [AHA 2016. Oral Presentation.](#)
29. **75B:** Impact of CHA2DS2-VASc Risk Factors on Anticoagulant Prescription in Patients with Atrial Fibrillation: Insights From the NCDR® PINNACLE Registry. L. Thompson. [AHA 2016. Oral Presentation.](#)
30. **86B:** Trends and Predictors of Statin Use Before and After the Publication of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Guideline on the Treatment of Blood Cholesterol: Insights from the NCDR® PINNACLE Registry. Y. Pokharel. [AHA 2016. Oral Presentation.](#)
31. **92:** Signs, Symptoms, and Treatment Patterns Across Serial Ambulatory Cardiology Visits in Patients with Heart Failure: Insights from the PINNACLE Registry. S. Turner. [AHA 2016. Oral Presentation.](#)
32. **75A:** Impact of CHA2DS2-VASc Risk Factors on Anticoagulant Prescription in Patients with Atrial Fibrillation: Insights From the NCDR® PINNACLE Registry. L. Thompson. [QCOR 2016. Oral Presentation.](#)
33. **86A:** Trends and Predictors of Statin Use Before and After the Publication of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Guideline on the Treatment of Blood Cholesterol: Insights from the NCDR® PINNACLE Registry. Y. Pokharel. [QCOR 2016. Oral Presentation.](#)
34. **50:** The Relationship Between Provider Experience and Cardiac Performance Measure Compliance in Outpatients: Results from the NCDR. N. Thande. [ACC 2015. Poster Presentation.](#)
35. **51:** Assessing the Validity of Physician Quality Reporting. W. Borden. [ACC 2015. Poster Presentation.](#)
36. **61:** Factors Associated with Use of Newer Antiplatelet Agents in Patients Undergoing Drug Eluting Stent Placement: Analysis from The Pinnacle® Registry. S. Bandiali. [ACC 2015. Poster Presentation.](#)
37. **23C:** Development of a Nationwide Ambulatory Cardiovascular Registry: An Update on PINNACLE-AF. B. Mullen. [ACC 2014. Poster Presentation.](#)

## June 2022

38. **26:** Use of Novel Oral Anticoagulants for Patients with Non-Valvular Atrial Fibrillation: Results from the NCDR PINNACLE Registry. N. Shah. [ACC 2014. Poster Presentation.](#)
39. **48:** Variation in Performance Measure Criteria for Million Hearts™ Significantly Affects Practice Rankings: Results from 3,630,462 Outpatients in 127 US Practices from the NCDR® PINNACLE Registry. Z. Eapen. [ACC 2014. Oral Presentation.](#)
40. **60A:** Frequency and Practice Level Variation in Inappropriate and Non-Recommended Prasugrel Prescribing: Insights from the NCDR®PINNACLE Registry. R. Hira. [ACC 2014. Young Investigator Award.](#)
41. **64:** Uptake of Novel Oral Anticoagulants in Patients with Non-Valvular and Valvular Atrial Fibrillation: Results from the NCDR-Pinnacle Registry. S. Jani. [ACC 2014. Poster Presentation.](#)
42. **70:** Predictors of Aspirin Versus Oral Anticoagulant Prescription in Atrial Fibrillation Patients At-Risk for Stroke: Insights from the NCDR® PINNACLE Registry. J. Hsu. [ACC 2014. Poster Presentation.](#)
43. **47:** Association between provider type and quality of outpatient cardiovascular care in the PINNACLE registry. S. Virani. [AHA 2014. Oral Presentation.](#)
44. **60B:** Practice Variation in Antiplatelet and Anticoagulation Therapy for Patients with Both Atrial Fibrillation and Coronary Artery Disease. J. Wasfy. [AHA 2014. Poster Presentation.](#)
45. **64:** Implications of the 2013 ACC/AHA Cholesterol Guidelines for Adults in Contemporary Cardiovascular Practice: Insights from the NCDR PINNACLE Registry. T. Maddox. [AHA 2014. Oral Presentation.](#)
46. **65:** Impact of the 2014 Expert Panel Recommendations for Management of High Blood Pressure on Contemporary Cardiovascular Practice: Insights from the NCDR® PINNACLE Registry®. W. Borden. [AHA 2014. Oral Presentation.](#)
47. **40:** Inappropriate Oral Anticoagulant Use in Atrial Fibrillation Patients with a Low Risk of Thromboembolism: Insights from the NCDR® PINNACLE Program. J. Hsu. [ACC 2013. Poster Presentation.](#)
48. **38:** Differences in Anticoagulant Therapy Prescription in Patients with Paroxysmal versus Persistent Atrial Fibrillation: Insights from the NCDR® PINNACLE Program. J. Hsu. [HRS 2013. Poster Presentation.](#)
49. **43:** Differences in the Compliance of Coronary Artery Disease (CAD) Performance Metrics and Statin Use in Patients who have Undergone Recent Coronary Artery Bypass Grafting (CABG) Compared to Those with Recent Percutaneous Coronary Intervention (PCI). S. Bandedali. [QCOR 2013. Poster Presentation.](#)
50. **44:** Relationship of Provider and Practice Volume to Performance Measure Adherence for Patients with Coronary Disease. L. Fleming. [QCOR 2013. Poster Presentation.](#)
51. **29:** Socioeconomic Disparities in Use of Cardioprotective Medications Among Patients with Peripheral Arterial Disease: An Analysis of the NCDR® PINNACLE Registry®. S. Subherwal. [ACC 2012. Presentation.](#)
52. **30:** Improving Practice-Based Learning for Fellows in Training with Cardiology's First Ambulatory Quality Improvement Registry: Observations from the PINNACLE Registry®. T. Singh. [ACC 2012. Poster Presentation.](#)
53. **22:** Role of Practitioners' Gender in Their Adherence to Performance Measures in Ambulatory Cardiology Practices: A Report from the NCDR®. D. Gupta. [AHA 2012. Oral Presentation.](#)
54. **35:** The Pragmatism Paradox: Rapidly scaling the ambulatory PINNACLE Registry without compromising data utility. J. B. Mullen. [China Outcomes Research and Evidence-based Medicine \(CORE\) Summit 2012. Oral Presentation.](#)

## June 2022

55. **23A:** Practice Level Variation in use of Recommended Medications among Outpatients with Heart Failure: A Report from the NCDR® PINNACLE Registry®. P. N. Peterson. [QCOR 2012. Poster Presentation.](#)
56. **23B:** Practice Variation is a Significant Contributor to Secondary Prevention Medication Use: Insights from the NCDR PINNACLE Program. T. M. Maddox. [QCOR 2012. Poster Presentation.](#)
57. **32:** Voluntary Registry Participation Rapidly Improves Physician Quality Performance: A Single Practice Experience. D. C. May. [QCOR 2012. Poster Presentation.](#)
58. **34:** Assessing Performance Perceptions and Realities in Outpatient Atrial Fibrillation Care. N. T. Glusenkamp. [QCOR 2012. Poster Presentation.](#)
59. **36:** Million Hearts™ and the PINNACLE Registry®: Preliminary Data. N. T. Glusenkamp. [QCOR 2012. Poster Presentation.](#)
60. **6B:** National Cholesterol Education Program (NCEP) Lipid Goal Achievement Beyond Low-density lipoprotein cholesterol (LDL-C) in Patients with Diabetes Mellitus (DM): Focus on Non-High-Density Lipoprotein Cholesterol (non-HDL-C) in the Practice Innovation and Clinical Excellence (PINNACLE) Program. S. A. Spinler. [American College of Clinical Pharmacy \(ACCP\) Annual Meeting 2011.](#)
61. **6A:** Achievement of NCEP-Recommended Lipid Goals in Patients with Dyslipidemia: Insights from the NCDR PINNACLE Registry. S. A. Spinler. [AHA 2011. Poster Presentation.](#)
62. **4A:** Unchanged Prescription of Dual Anti-Platelet Therapy Following CHARISMA: A Report from the NCDR® PINNACLE Registry®. A. M. Goldsweig. [QCOR 2011.](#)
63. **4B:** Trends in the Use of Dual Anti-Platelet Therapy for Atrial Fibrillation and Chronic Cardiovascular Disease. Chen. [QCOR 2011. Poster Presentation.](#)
64. **5:** Medication Therapy Management Services - A Requirement for Medicare Part D Plans: Are your Patients Eligible? S. A. Spinler. [QCOR 2011. Poster Presentation.](#)
65. **11:** Use of Statins in Outpatients with Coronary Artery Disease. Insights from the PINNACLE Registry. S. Arnold. [QCOR 2011. Poster Presentation.](#)
66. **9A:** Sex Differences in Outpatient Performance Measures: A Report of the first 14,000+ Patients in the American College of Cardiology's IC3 (Improving Continuous Cardiac Care) Program. P. Chan. [ACC 2010. Poster Presentation.](#)
67. **9B:** The American College of Cardiology's IC3 (Improving Continuous Cardiac Care) Program and Heart Failure Performance Measures: A Report of the first 14,000+ Patients. P. Chan. [ACC 2010. Poster Presentation.](#)
68. **N/A (IC3-10):** Racial Differences in Outpatient Performance Measures: A Report of the first 10,000+ Patients in the American College of Cardiology's IC3 (Improving Continuous Cardiac Care) Program. P. Chan. [ACC 2010. Poster Presentation.](#)
69. **N/A (IC3-12):** Outpatient Compliance with Performance Measures for Atrial Fibrillation: A Report of the first 14,000+ Patients from the American College of Cardiology's IC3 (Improving Continuous Cardiac Care) Program. P. Chan. [ACC 2010. Oral Presentation.](#)
70. **N/A (IC3-18):** Feasibility of developing and implementing a national practice-based quality improvement program quality improvement: Results from the IC3 Program pilot. F. Fiocchi. [Academy Health 2010. Poster Presentation.](#)
71. **1:** Health Care Insurance Status and Cardiac Performance Measure Compliance: Insights from the ACC's NCDR PINNACLE Registry. Smolderen. [AHA 2010. Poster Presentation.](#)



## June 2022

72. **2:** Practice-Level Variation in Cardiac Performance Measure Compliance: Insights from the ACC's NCDR PINNACLE Registry. Chan. [AHA 2010. Poster Presentation.](#)
73. **N/A (IC3-19):** Building quality improvement from the ground up: Lessons from the design and implementation of the IC3 Program national practice-based quality improvement program. M. Elma. [QCOR 2010. Poster Presentation.](#)
74. **N/A (IC3-20):** Implementing an Orientation and Training Program for Quality Improvement in the Office-based Setting: Initial Observations from the American College of Cardiology Improving Continuous Cardiac Care (IC3) Pilot Program Assessing the Feasibility of Implementing a Clinical Decision Support Tool in the Office-based Setting: Experiences from the American College of Cardiology's Improving Continuous Cardiac Care (IC3) Pilot Program. K. Kehoe. [QCOR 2010. Poster Presentation.](#)
75. **N/A (IC3-21):** Implementation of the PINNACLE Registry TM: Initial Experience and Insights from a Large Cardiovascular Practice in Texas. D. May. [QCOR 2010. Poster Presentation.](#)
76. **N/A (IC3-22):** Utilization of a Clinical Registry to Drive Practice-Based Learning and Improvement among Cardiology Fellows in Training: Observations from the American College of Cardiology's PINNACLE Registry. M. Frederick. [QCOR 2010. Poster Presentation.](#)
77. **N/A (IC3-13):** Building quality improvement from the ground up: Lessons from the design and implementation of the IC3 Program national practice-based quality improvement program. J. Wright. [World Congress of Cardiology 2010. Oral Presentation.](#)
78. **N/A (IC3-7):** The American College of Cardiology's IC3 (Improving Continuous Cardiac Care) Program: A Report of the first 10,000+ Patients. P. Chan. [AHA 2009. Oral Presentation.](#)
79. **N/A (IC3-8):** Electronic Medical Record Adoption in Cardiology Practices: A 2009 Snapshot from the American College of Cardiology's IC3 (Improving Continuous Cardiac Care) Program. K. Mitchell. [AHA 2009. Poster Presentation.](#)
80. **N/A (IC3-3):** The role of strategic alliances as a key success factor in the development of a national quality improvement program for office-based cardiology practices in the U.S. F. Fiocchi. [QCOR 2009.](#)
81. **N/A (IC3-4):** Claims verse Clinical Data Conundrum: Can Two Disparate Data Sources Measure Physician Performance for the Same Purpose in the Same Way: The PQRI Registry Alternative Perspective. P. Jones. [QCOR 2009.](#)
82. **N/A (IC3-5):** Challenges of Implementing Cardiac Performance Measures: Insights from the IC3 Program. J. Spertus. [QCOR 2009.](#)
83. **N/A (IC3-6):** Barriers and Facilitators to Implementing a Local Health Information Technology Initiative: Lessons Learned from a Local IC3 Program Pilot. K. Mitchell. [QCOR 2009.](#)

June 2022

## PVI Registry™

1. **19:** In-Hospital Outcomes and Discharge Medication Use Among Patients Presenting with Critical Limb Ischemia Versus Claudication: Insights from the NCDR PVI Registry. J. Rymer. **ACC 2019. Oral Presentation.**
2. **20:** A Risk Model of Acute Kidney Injury in Patients Undergoing Peripheral Vascular Intervention: From the National Cardiovascular Data Registry Peripheral Vascular Intervention (NCDR PVI) Registry™. E. Sefley. **AHA 2018.**

**June 2022**  
**STS/ACC TVT Registry™**

1. **416:** Incidence, Predictors, and Clinical Impact of Recovery in Left Ventricular Systolic Function After Transcatheter Aortic Valve Implantation in the STS/ACC TVT Registry. S. Patel. [ACC 2022. Poster Presentation.](#)
2. **479:** Comparing Volume Versus Quality Thresholds on Outcomes and Access to Transcatheter Aortic Valve Replacement (TAVR) in the United States: Insights from the TVT Registry. A. Nelson. [ACC 2022. Moderated Poster Presentation.](#)
3. **573:** Correlation Between Hospital Procedural Volumes and Outcomes for TAVR And MTEER In the United States: An STS/ACC TVT Registry Analysis. D. Kumbhani. [ACC 2022. Poster Presentation.](#)
4. **N/A:** Validation of the STS/ACC TVT Risk Score In Patients Undergoing Transcatheter Aortic Valve Replacement Stratified By Risk. [ACC 2022. Moderated Poster Presentation.](#)
5. **431:** National Trends in Permanent Pacemaker Implantation after Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry. K. Chau. [TCT 2021. Oral Presentation.](#)
6. **561:** Outcomes of Transcatheter Aortic Valve Replacement with a Balloon-Expandable Valve for Bicuspid vs Tricuspid Aortic Stenosis. R. Makkar. [TCT 2021. Oral Presentation.](#)
7. **342:** Peripheral versus Central Access for Alternative Access Transcatheter Aortic Valve Replacement (TAVR): Results from the TVT Registry. T. Kaneko. [ACC 2020. Virtual Poster Presentation.](#)
8. **350A:** Low Body Mass Index is Associated with Higher Rates of Death in Patients Undergoing Transcatheter Mitral Valve Repair: A Report from the STS/ACC TVT Registry TM. Arora. [ACC 2020. Poster Presentation.](#)
9. **413:** Conscious Sedation versus General Anesthesia for Transcatheter Aortic Valve Replacement: Variation in Practice and Outcomes in the STS/ACC TVT Registry. Butala. [ACC 2020. Virtual Poster Presentation.](#)
10. **440:** Acute Kidney Injury in Transcatheter Aortic Valve Replacement. H. Julien. [CRT 2020. Poster Presentation.](#)
11. **350B:** Relationship of Body Mass Index with Outcomes After Transcatheter Aortic Valve Replacement: Results from the National Cardiovascular Data–STS/ACC TVT Registry. A. Sharma. [Mayo Clinic Proceedings 2020. Oral Presentation.](#)
12. **421:** Institution-Level Variability in 30-day Patient Outcomes after Transcatheter Mitral Valve Repair in the United States. Malik. [QCOR 2020. Poster Presentation.](#)
13. **422:** Patient-Reported Health Status Changes is Associated with Subsequent Clinical Outcomes After Transcatheter Valve Therapies: Insights from the STS/ACC TVT Registry. Hejjaji. [QCOR 2020.](#)
14. **472:** Association of Cerebral Embolic Protection Devices with Transcatheter Aortic Valve Replacement Outcomes: Results from the STS/ACC TVT Registry. Butala. [TCT Connect 2020. Oral Presentation.](#)
15. **518:** Outcome of Redo TAVR for failing transcatheter heart valves. A. Zajarias. [TCT 2020. Poster Presentation.](#)
16. **592:** Redo Transcatheter Aortic Valve Replacement with the Supra-Annular, Self-Expandable Evolut Platform: Insights from the TVT Registry. Harvey. [TCT 2020. Oral Presentation.](#)
17. **258:** Pre versus post-procedure clinical event rates and associated healthcare resource utilization in patients who undergo commercial Mitra Clip placement for severe mitral regurgitation. S. Vemulapalli. [ACC 2019. Poster Presentation.](#)

## June 2022

18. **353:** Sex-Based Differences in Outcomes After Transcatheter Repair of Mitral Regurgitation with the Mitra Clip System. P. Villablanca. [ACC 2019. Moderated Poster Presentation.](#)
19. **639:** Variation in post-TAVR Antithrombotic Therapy and Outcomes in Patients with Preexisting Atrial Fibrillation: Insights from the STS/ACC TVT® Registry. Gupta. [AHA 2019. Poster Presentation.](#)
20. **N/A.** Variation in post-TAVR Antithrombotic Therapy and Outcomes in Patients with Preexisting Atrial Fibrillation: Insights from the STS/ACC TVT® Registry. Gupta. [AHA 2019. Oral Presentation.](#)
21. **357:** Does Driving Time to the Transcatheter Aortic Valve Replacement Site Impacts on Long-Term Mortality Following a Successful Procedure? Insights from the STS/ACC TVT Registry. G. Marquis-Gravel. [QCOR 2019. Poster Presentation.](#)
22. **371:** Learning curve for transcatheter mitral repair: Insights from the STS/ACC TVT Registry. A. Chhatrwalla. [TCT 2019. Late Breaking Clinical Trial Presentation.](#)
23. **456:** Incidence and Outcomes of Patient-Prosthesis Mismatch Following Self-Expanding Transcatheter Aortic Valve Replacement in Native Aortic Stenosis: An Analysis from the STS/ACC TVT Registry. G. Tang. [TCT 2019. Poster Presentation.](#)
24. **215:** Atrial Fibrillation Is Associated with Higher Rates of Death and Heart Failure Hospitalizations in Patients Undergoing Mitra Clip: Outcomes from the TVT Registry. Arora. [ACC 2018. Poster Presentation.](#)
25. **249:** Outcomes After Transcatheter Mitral Valve Repair in Patients with Chronic Kidney Disease: An Analysis of 5,241 Patients in the United States. B. Shah. [ACC 2018. Poster Presentation.](#)
26. **254:** Outcomes Following Urgent/Emergent Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry. D. Kolte. [ACC 2018. Moderated Poster.](#)
27. **260:** High Hospital Variability in Mortality After TAVR Can Be Explained by Differences in Failure to Rescue from Post Procedural Complications. Bishawi. [ACC 2018. Moderated Poster.](#)
28. **267:** The Effect and Relationship of Age and Frailty on Survival in Patients Undergoing Transcatheter Aortic Valve Replacement. Kiani. [ACC 2018. Moderated Poster.](#)
29. **291:** Racial / Ethnic Disparities in Baseline Characteristics and 1-Year Outcomes After TAVR: A Report from the Transcatheter Valve Therapy (TVT) Registry. Vemulapalli. [AHA 2018. Moderated Poster Presentation.](#)
30. **224:** Association of renin-angiotensin system inhibition with clinical outcomes in patients undergoing transcatheter aortic valve replacement: analysis from the STS/ACC TVT Registry. Inohara. [Euro PCR 2018.](#)
31. **256:** 30-day outcomes of transcatheter mitral valve replacement in native mitral valve disease with severe mitral annular calcification in the United States: Data from the STS/ACC/TVT Registry. M. Guerrero. [Euro PCR 2018. Late Breaking Clinical Trial Poster Presentation.](#)
32. **450:** Real World Outcomes of TAVR with the SAPIEN-3 Valve in Intermediate Risk Patients: Comparison of Data from the TVT Registry with PARTNER S3 Studies. Tuzcu. [Euro PCR 2018. Oral Presentation.](#)
33. **194:** Incidence and Risk Factors of Aborted Procedures and Emergent Conversion to Surgery During Elective TAVR. T. Wang. [TCT 2018. Oral Presentation.](#)
34. **263:** Incidence and Risk Factors for Early Stroke after Transcatheter Aortic Valve Replacement: Insights from the STS-ACC TVT Registry. C. Huded. [TCT 2018. Poster Presentation.](#)
35. **264:** Incidence, Predictors, and Outcomes of Prosthesis-Patient Mismatch in 62,125 TAVR Patients An STS/ACC TVT Registry Report. H. Herrmann. [TCT 2018. Oral Presentation.](#)

## June 2022

36. **272:** Quality of Life Outcomes After MitraClip in a Real-World Population. Results from the STS/ACC Transcatheter Valve Therapy Registry. S. Arnold. **TCT 2018. Oral Presentation.**
37. **285:** Change in Mitral Valve Gradient Following Mitra clip Repair and Correlation to 30-day and 1-year outcomes. V. Assche. **TCT 2018.**
38. **7:** Patterns of Red Blood Cell Transfusion and Associated Outcomes in patients undergoing TAVR in the U.S.: Insights from the STS/ACC TVT Registry. M. Sherwood **ACC 2017. Poster Presentation.**
39. **114:** Impact of the Presence of Coronary Artery Disease and Timing of Revascularization on Outcomes of Patients Undergoing Trans-Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry. H. Tankazyan. **ACC 2017. Poster Presentation.**
40. **130:** Direct-home discharge and likelihood of 30-day hospital readmission after transcatheter aortic valve replacement (TAVR): Findings from the STS/ACC TVT Registry. J. Dodson **ACC 2017. Poster Presentation.**
41. **153:** Prevalence and Outcomes of Mitral Stenosis in Patients Undergoing Transcatheter Aortic Valve Replacement: Findings from the Society of Thoracic Surgeons/ American College of Cardiology (STS/ACC) Transcatheter Valve Therapies (TVT) Registry. L. Joseph. **ACC 2017. Poster Presentation.**
42. **155:** New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: Incidence, Anticoagulant Strategy, and Outcomes. A. Vora. **ACC 2017. Oral Presentation.**
43. **156:** Incidence and Outcomes of Patients Requiring Surgical Bail-Out during Transcatheter Aortic Valve Replacement from the NCDR® STS/ACC TVT Registry. A. Moldonado. **ACC 2017. Moderated Poster Presentation.**
44. **190:** Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the STS/TVT Registry. A. Fanaroff. **ACC 2017. Poster Presentation.**
45. **191A:** Stroke and Cardiovascular Outcomes in Patients with Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry. A. Kochar. **ACC 2017. Poster Presentation.**
46. **191B:** Stroke and Cardiovascular Outcomes in Patients with Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry. Kochar. **ACC 2017. Poster Presentation.**
47. **245B:** Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Valve Repair in the United States. P. Sorajja. **ACC 2017. Featured Clinical Research Oral Presentation.**
48. **269:** Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis from Two US Registries Linked to Medicare Data. M. Brennan. **ACC 2017. Featured Clinical Research.**
49. **N/A:** Incidence and Outcomes of Patients Requiring Surgical Bail-Out During Transcatheter Aortic Valve Replacement: A Report From the NCDR® STS/ACC Transcatheter Valve Therapy (TVT) Registry. Pineda. **ACC 2017. Poster Presentation.**
50. **186:** Effects of Fragmentation of Post-Procedural Care on Outcomes after TAVR. Wang. **AHA 2017. Poster Presentation.**
51. **200:** Transcatheter Aortic Valve Replacement Using the Self-Expanding Bioprosthesis: First Report from the Transcatheter Valve Therapies Registry. J. Popma. **TCT 2017. Poster Presentation.**
52. **333:** Impact of atrial fibrillation on clinical outcomes in patients treated with self-expanding transcatheter aortic valves in the United States: Results from the STS/ACC TVT Registry. Chandrasekhar. **TCT 2017. Moderated Poster.**
53. **98:** Impact of pulmonary hypertension on outcomes of patients undergoing transcatheter aortic valve replacement: Report from the TVT registry. C. Don. **ACC 2016. Oral Presentation.**

## June 2022

54. **105:** Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement: Analysis of the STS/ACC TVT Registry. Fadahunsi. **ACC 2016. Oral Presentation.**
55. **106:** Procedure Volume and Outcome for Transcatheter Aortic Valve Replacement in U.S. Clinical Practice. J. Carroll. **ACC 2016. LBCT Oral Presentation.**
56. **133:** Transcatheter Aortic Valve Replacement is Associated with Fewer Hospital Days: A Report from the STS / ACC TVT Registry. D. Holmes. **ACC 2016. Poster Presentation.**
57. **406:** Incidence and Outcomes of Hemodynamic Deterioration in Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: A Report from the Society of Thoracic Surgery / American College of Cardiology Transcatheter Valve Therapy Registry. S. Vemulapalli. **ACC 2016. LBCT Oral Presentation.**
58. **240:** Development of a Risk Prediction Model for 1-Year Mortality after Surgical vs. Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis. S. Baron. **AHA 2016. Poster Presentation.**
59. **90:** Sex Based Differences in Outcomes with Transcatheter Aortic Valve Therapy: From the STS/ACC TVT Registry. Chandrashekar. **SCAI 2016. LBCT Poster Presentation.**
60. **58:** Transcatheter Aortic Valve in Valve Replacement for Degenerative Aortic Bioprosthesis: Initial Results from the STS/ACC Transcatheter Valve Therapy Registry. Tuzcu. **TCT 2016. LBCT Oral Presentation.**
61. **110:** Incidence and Outcomes of Vascular Complications and Bleeding Events in Patients undergoing TAVR in contemporary U.S. practice: Insights from the STS/ACC TVT Registry<sup>®</sup>. M. Sherwood. **TCT 2016. Oral Presentation.**
62. **174:** The Impact of Diabetes Mellitus on the Clinical Outcomes Following Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry. Abramowitz. **TCT 2016. LBCT Poster Presentation.**
63. **245A:** Outcomes in the Commercial Use of Self-Expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic Core Valve and Evolut R platforms in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. P. Sorajja. **TCT 2016. Oral Presentation.**
64. **33:** Incremental Value of Disease-Specific Health Status in Predicting Mortality after Transcatheter Aortic Valve Replacement. S. Arnold. **ACC 2015. Poster Presentation.**
65. **36:** Acute Kidney Injury in Transcatheter Aortic Valve Replacement: Can We Reduce the Risk? Brooks. **ACC 2015. Poster Presentation.**
66. **37:** Impact of Baseline Left Ventricular Function and Aortic Valve Gradient on Outcomes in Patients Treated with Transcatheter Aortic Valve Replacement: Results from the TVT Registry. S. Baron. **ACC 2015. Oral Presentation.**
67. **109:** Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the United States. P. Sorajja. **ACC 2015. Poster Presentation.**
68. **200:** Transcatheter Aortic Valve Replacement Using the Self-Expanding Bioprosthesis: First Report from the Transcatheter Valve Therapies Registry. J. Popma. **TCT 2015. Poster Presentation.**
69. **8:** One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry. D. Holmes. **ACC 2014. Late-Breaking Clinical Trial: Oral Presentation.**
70. **58:** Transcatheter Aortic Valve in Valve Replacement for Degenerative Aortic Bio prosthesis: Initial Results from the STS/ACC Transcatheter Valve Therapy Registry. M. Tuzcu. **ACC 2014. Oral Presentation.**

## June 2022

71. **101:** The Outcomes of Transcatheter Aortic Valve Replacement in Patients with Bicuspid Aortic Stenosis: Insights from the STS/ACC TVT Registry. F. Edwards. ACC 2014. Oral Presentation.
72. **N/A:** ESRD: M. Mack. ACC 2014. Oral Presentation.
73. **N/A:** The Outcomes of Transcatheter Aortic Valve Replacement in Patients with Bicuspid Aortic Stenosis: Insights from the STS/ACC TVT Registry. F. Edwards. ACC 2014. Oral Presentation.
74. **N/A:** Transcatheter Aortic Valve in Valve Replacement for Degenerative Aortic Bioprosthesis: Initial Results from the STS/ACC Transcatheter Valve Therapy Registry. M. Tuczu. ACC 2014. Oral Presentation.
75. **3:** The Association of Transcatheter Aortic Valve Replacement (TAVR) Availability, Surgical Aortic Valve Replacement Case Volume, and In-hospital Mortality in the United States. A Report from the STS National Database and the STS/ACC TVT Registry. J. M. Brennan. STS 2014. Oral Presentation.
76. **44:** Comparison of Alternative Access TAVR Techniques in the United States for Patients Considered High-Risk or Inoperable for Aortic Valve Replacement and with Severe Aortic Stenosis. V. Thourani. STS 2014. Oral Presentation.
77. **74:** The Prognostic Impact of Chronic Lung Disease in 12,139 Patients Undergoing Transcatheter Aortic Valve Replacement: Results from the STS/ACC-TVT Registry. R. Suri. STS 2014. Oral Presentation.